Skip to main content
PLOS One logoLink to PLOS One
. 2022 Jan 24;17(1):e0261661. doi: 10.1371/journal.pone.0261661

General practitioners and sales representatives: Why are we so ambivalent?

Adriaan Barbaroux 1,2,*, Isabelle Pourrat 1, Tiphanie Bouchez 1
Editor: Barbara Mintzes3
PMCID: PMC8786166  PMID: 35073342

Abstract

Introduction

Accepting gifts from pharmaceutical sales representatives (sales reps) or meeting them is correlated with excessive, more expensive and sometimes less rational prescribing. French general practitioners (GPs) tend to hold an unfavorable opinion of the pharmaceutical industry, yet the behavior they adopt with sales reps is generally favorable. Until now, no study has sought to explain the reasons for this discrepancy. This study explores GP experiences to better understand their ambivalent behavior.

Method

This qualitative descriptive study was based on semi-structured face-to-face interviews with French GPs in the south-east of France. An interpretative phenomenological approach was chosen to explore individual professional practices and to model the phenomenon through in-depth analysis of semi-structured interviews. A general inductive analysis was carried out. Data were analyzed by researchers from different disciplines (psychology, sociology and general practice).

Results

Ten GPs were interviewed for an average of 50 minutes. The analysis revealed three forces that combine to motivate GPs to keep meeting sales reps despite their unfavorable opinion of these visits: practical reasons such as the need for a substitute for continuing education; social and cultural reasons such as courtesy towards representatives; and psychological mechanisms such as cognitive dissonance and a hidden curriculum.

Discussion

The GP-representative relationship is complex and involves psychological mechanisms that the medical profession often fails to recognize. GPs use reps as a convenient tool for continuing education, particularly in the setting of a private practice where GPs feel pressed for time. Cognitive dissonance is a well-supported theory in social psychology that explains how a person maintains a behavior while having an unfavorable opinion of it. Since GP meetings with sales reps start during their internship, they could also be considered as part of a hidden curriculum. The strength of this work is to combine medical, social psychological and sociological perspectives with the original interpretative phenomenological approach. When the veil is lifted on individual ambivalence, the questions raised are more social and political than individual.

Introduction

In the United States of America (USA), the biopharmaceutical sector generates nearly $1.2 trillion in economic output annually when direct (biopharmaceutical industry revenue), indirect (vendor and supplier activity), and induced effects (additional private economic activity) are considered [1]. Financial relationships between the leaders of influential professional USA medical associations and industry are extensive: 72% of such associations have financial ties to industry [2]. The marketing of opioid products to physicians in the USA was associated with increased opioid prescribing and higher mortality from overdoses [3]. The pharmaceutical industry in France has one of the largest promotional budgets of any country [4]. The pharmaceutical industry represents 100,000 jobs, and with its 54-billion-euro annual turnover, is the fourth biggest contributor to the French Trade Balance (0.15% of the Gross Domestic Product). The role of pharmaceutical sales representatives (sales reps) is regulated by the government through a Sales Visit Charter and a certification procedure but, despite more stringent regulatory requirements than in North America, the information concerning drugs provided by sales reps to GPs remains poor [5, 6]. The Sales Visit Charter promotes good practices such as the presentation of approved product information including side effects and contraindications. Despite strict regulations (health authorities can impose fines of up to €10,000 or 10% of a product’s annual sales revenue) [7], key provisions within the Sales Visit Charter, such as mentioning adverse effects, precautions and contraindications are rarely respected [5, 6]. Pharma sales reps are not allowed to provide content for continuing education courses. A national fund for continuing medical education finances free courses for GPs and compensation for the loss of three days’ worth of medical income while training. This non-biased continuing medical education is mandatory [8]. Initial and continuing medical education are supposed to be provided by impartial experts but these experts can be opinion leaders with financial ties to the industry [912]. Despite these measures, the pharmaceutical industry still plays an active role in research and in general practitioner (GP) training from the preclinical years to continuing medical education [11]. The French National Health Authority, “Haute Autorité de Santé” (HAS), encourages professionals and health care facilities to address the issue of sales visits and provides tools such as a French translation of the World Health Organization’s guide “Understanding and responding to pharmaceutical promotion: a practical guide”. HAS also provides guidance to health care facilities on how to regulate sales visits [13, 14].

French primary care is mainly organized as a private, independent service, although financed by the public health system. Like most primary care providers in France, GPs mainly work in private practice and are paid on a fee-for-service basis. Group practice is now dominant among GPs and 81% of GPs younger than 50 declare that they work in a group [15]. Since the 2000s, teamwork in multidisciplinary primary care centers has been developed, mainly to maintain primary care services in low-income areas. In France, GPs meet an average of 5.6 sales reps per week, and spend an average of 55 minutes per week with them [16]. Nine out of ten GPs in France were offered a gift from a pharmaceutical company between 2011 and 2016 [17].

Accepting gifts from sales reps or meeting them is correlated with excessive, more expensive and less rational prescribing [18]. A recent study confirmed this finding about French GPs using indicators such as the prescription of antibiotics, benzodiazepines and vasodilators [17]. Free drug samples and gifts of food and drink in the office are not allowed in France, but GPs still receive gifts and invitations to restaurants since the law allows for exceptions. Promotional budgets could therefore be viewed as an investment that ensures an increase in the number of prescriptions [4, 17, 19]. A report by the French Inspectorate General of Social Affairs (Inspection Générale des Affaires Sociales–IGAS) studied the information GPs receive about drugs. The report concluded that, after the drug database Vidal, sales rep visits were the second most used source of information for practitioners, despite a negative opinion held against detailing visits [4]. This situation is problematic on a financial level (costs are indirectly born by the community via medication prices) as much as on a social and ethical level (citizens’ demand for more transparency and more independent training for prescribers) and on a public health level because of potentially inadequate prescribing practices [4, 20, 21]. Therefore the independence of prescribers remains an essential goal [22].

In 2003, British GPs reported that they received visits from sales representatives for six major reasons: the convenience and availability of information about drugs; the legitimacy of reps as a source of information; out of courtesy; to receive gifts; social and intellectual interaction; to conform with organizational and cultural norms [23]. The reasons GPs gave for seeing reps were reported in “neutral” and “legitimate” terms, as GPs largely believed in their own immunity to commercial marketing strategies. Another qualitative study pointed out that French GPs’ interactions with sales reps provided them with information that was easy to access and easy to use [24]. GPs also described a lack of confidence in their own pharmaceutical knowledge when leaving university [24].

These observations highlight the seemingly ambivalent position of GPs, who believe in their own ability to resist the influence of reps but not necessarily in the ability of other GPs [9]. They are well aware of the reps’ commercial role and hold a rather negative opinion of them, describing reps as advertisers who are trying to influence them to prescribe in a less efficient way [3]. However, their behavior remains rather favorable towards the pharmaceutical industry, as they still predominantly receive sales rep visits (80% of practitioners in France) [11, 23, 25]. So far, no study has attempted to understand the ambivalence of GPs: why do so many of them receive sales rep visits even though they hold a rather negative opinion of the pharmaceutical industry? This study explores GP experiences to better understand their ambivalence.

Method

General design

An exploratory qualitative study was conducted based on a constructivist paradigm [26]. In this paradigm, qualitative research methods are considered as a means to allow the investigator to be the primary interpretive instrument and reality is considered as socially constructed and knowledge as a product constructed by people taking active part in a research process [26]. An interpretative phenomenological approach was used, that is, individual professional practices were explored and the phenomenon was modeled through the in-depth analysis of singular experiences, the meaning that participants gave to their experience of meeting sales reps, and the underlying psychological mechanisms [27]. The purpose of a phenomenological approach is mainly to shed light on the essence of a person’s experience in relation to a specific phenomenon, in this instance meeting sales reps despite holding a negative opinion of them. In a phenomenological study, sample sizes are typically small because data saturation is not essential if the objective is to understand the meaning individuals give to their own lived experience [28]. Semi-structured interviews with general practitioners were conducted face to face as appropriate for the intimacy of the attitude being explored. Each interview was recorded and transcribed verbatim. Field notes were taken during the interviews and immediately after.

Transcripts were analyzed one interview at a time to explore individual perspectives. Texts were commented on, then themes were coded, organized and finally formulated to identify common patterns shared by the different experiences [27, 2931]. Results were interpreted by a multi-field team composed of three GPs (AB, IP, TB), a sociologist (IF), and a social psychologist (IM). The heterogeneity of the team’s skills aimed at identifying a broader range of themes to enlarge the scope of the analysis.

The interviews were conducted at the GP’s office by a male family medicine resident (AB) previously trained by members of the research team (IP, IF). The practitioners were asked to react to a series of three clinical scenarios through open questions (the interview guide is available in S1 Appendix). The clinical scenarios represented current situations encountered by general practitioners in their work and the information sources they can turn to. The interview guide was developed from existing literature [24] (identifying professional situations of uncertainty and reasons for meeting sales reps) and from two preliminary interviews. Both preliminary interviews were based on an interview guide with open questions relating to the relationship with sales reps (“What do you expect from a sales rep?” “Can you describe the way your last encounter with a rep went?”). Both practitioners interviewed showed signs of defense mechanisms related to social desirability [32]. Thus, the guide structure was modified to include the three clinical scenarios. The data from the preliminary interviews was retained in this study, in accordance with the standards in qualitative research [27, 29]. The modified interview was designed to elicit the same reflections and allow the GPs to address sales rep visits by means of the scenarios without requiring the investigator to mention them. Each participant discussed the three scenarios. The scenarios presented a short story describing GPs in a situation of doubt and the way they would react to it (for instance by seeking the advice of a fellow GP, or by prescribing a new drug discovered during a conference). This context was chosen because of previous evidence that in a situation of doubt a practitioner is the most sensitive to the influence of sales reps [9]. The scenarios served to gradually bring up the issue of sales rep visits without causing the reluctance and social desirability bias observed in the two preliminary interviews. The questions that followed the three scenarios were similar (“What sources of information do you regularly use?”–“Can you tell me more about sales reps?”). The next questions aimed at progressively focusing on the GP-rep relation (“Have you ever considered no longer meeting reps?”–“I am particularly interested in the apparent contradiction between what you tell me”“and, at the same time,“How did you come to this opinion?”). Some questions were not directly related to sales reps in order to avoid the defensive reactions observed in the preliminary interviews. The second and the third scenarios only served to renew the discussion when necessary by moving on to the next scenario. The first scenario concerned the prescription of sitagliptin to a frail patient, the second the switch to oral anticoagulation in an elderly and poly-medicated patient and the third the prescription of rivaroxaban to a young patient with paraphlebitis, following the advice of a colleague.

Population and recruitment

A convenience sampling method was used to select people with a range of experience in meeting sales reps. No specific inclusion or non-inclusion criteria were imposed since the research team considered that any GP could contribute new data to explain the phenomenon studied. The selection of practitioners was based on variability criteria for the following characteristics: age, gender, rural location, years of practice, patient list size, single or collective practice, and paid subscription to a journal or membership in a peer group (see chart no. 1). Peer groups are structured small groups of 6 to 12 health care professionals who meet regularly to reflect on and improve their practice. They also serve to develop professional networks. They are very popular in France, where participation can give rise to a government payment to members when the group is accredited (registered and recognized by the government) [33]. These characteristics were expected to lead to a diverse sample of experiences and were based on the literature describing how the GP-rep relationship depends on social norms, age, patient list size and the type of continuing medical education [4, 24]. Participants were asked about these characteristics at the end of the interview.

The GPs’ phone numbers were found in the phone book. They were recruited in a coastal city with a population of more than 300,000 people in the south of France and in three neighboring towns of 1,300–7,000 people. The GPs were asked to answer a survey as part of an end of course medical thesis. The survey was presented to them as dealing with the information sources used by general practitioners, without mentioning promotional detailing visits. Ten GPs declined to participate because of a lack of time.

Validity and reliability

The research protocol and the presentation of results are based on COREQ criteria (COnsolitaded criteria for REporting Qualitative research), see S1 Checklist for further information. For confidentiality reasons, some of the information such as the gender of interviewed participants is not presented and no personal characteristics such as gender that might identify a speaker are attached to specific quotes.

Written consent was obtained from each participant. Ethics approval was not required because of the non-pharmaceutical bio-medical nature of this research [34]. Ethical aspects nevertheless respect the French legislation for data collected before January 2016. The authors did not receive any funding for this study.

This research article is part of the thesis work of a male general medicine resident who was in charge of collecting data. This main investigator studied reference material [2931, 3538] beforehand to gain knowledge in qualitative research, and obtained the assistance of researchers in social psychology, sociology and general practice who formed a workgroup specifically for this study. The main investigator examined his own assumptions, and his reasons and interests for studying the research topic by brainstorming with the research team before the research started.

Thematic extraction was triangulated to discuss and enrich interpretation from different perspectives: all interviews were analyzed first by the principal investigator, then by another researcher (GP, psychologist, or sociologist). The analyses were convergent (no disagreements arose between the surveyors) and complementary (they helped identify new themes). The research team discussed the data sample and considered that it gathered a wide range of experiences about relationships with sales reps and no new theme emerged from the material analyzed. Theoretical validation was obtained by comparing the results with existing scientific data (see Discussion).

The relevant datasets are available on request to the corresponding author.

Results

The material is composed of 10 interviews carried out from April to December 2014, of an average duration of 50 minutes (median of 46 minutes), for a total duration of 8 hours and 22 minutes.

The ten practitioners were 30 to 59 years old, and almost all of them charged the approved National Health rate. Two of them were women. Six of them worked in an urban environment; the other four worked in rural or semi-rural areas. One practitioner no longer received detailing visits. Two GPs received one sales rep visit a day, and one met with ten a week. Only one of them had a paid subscription to an independent journal, four of them declared reading free journals, and three took part in peer groups. These characteristics are summed up in Table 1.

Table 1. Demographics and practice characteristics of the ten GPs interviewed.

(Mean ± SD [Range])
Age (years) 48,8 ± 9 [3059]
Years in practice 15 ± 11 [134]
Enrolled patients 906 ± 439 [400–1500]
Hours p. week workload 55 ± 8 [43–65]
Number of sales reps per week 3 ± 3 [0–10]
(n—percentage)
Urban setting 6 (60%)
Group practice 5 (50%)
Reads commercially-produced free GP journals 4 (40%)
Subscribes to a paid medical journal 1 (10%)
Member of GP peer group 3 (30%)
Patients charged extra fees 1 (10%)

All but one GP spontaneously mentioned sales reps when discussing the scenarios. When the physician did not address the issue spontaneously, the interviewer raised the subject specifically. The three scenarios did not each elicit a different pattern of responses, which was expected since the research question was not about the drugs discussed in the scenarios, but about the GP-rep relationship. Transcripts, or excerpts of responses, can be grouped into the following categories: motivations, physicians’ perceptions, and values.

Motivations

Here, “motivations refer to the reasons GPs gave to explain why they meet sales reps.

The need for information was the motivation most often mentioned by practitioners to justify receiving sales rep visits despite their negative opinion about these interactions. The visits were described as practical, approachable, and sometimes of a good quality. This practicality justified the preference of sales rep visits over other information sources. “What’s important for the doctor is for it to be fast, concise, and straight to the point.”

The participants attributed to rep visits a reassurance effect regarding their knowledge, and a “starter” effect as the first link of the information chain: meeting a sales rep was said to trigger more extensive research.

A social role was also attributed to sales reps, by providing a human relationship with the representative (felt like a “break”) and by creating a medical “network” through sponsored meetings.

Professional constraints were also mentioned: “It’s true that I can’t attend FMC [Formation Médicale Continue–Continuing Medical Education] as often as I’d like, so I’ll admit that I enjoy having reps come [to my door].”

Physicians’ perceptions

Here, “physicians’ perceptions” refers to the perceptions and mental pictures that practitioners have of detailing visits and of their alternatives.

The physicians’ perceptions of the sales reps were lukewarm, going from “It’s a lot of nonsense, they’re selling that as if they were selling socks” to “he’s well trained”, “bulletproof”, “well-oiled.” Interviewed GPs raised few safety concerns about meeting reps: “A few years ago, they had become the only source of information. I mean that those who didn’t read ‘La Revue Prescrire’, they’d prescribe; they followed the information brought by the visitors. It’s dangerous to do that! But that’s changed; it’s changed a lot.” None of them talked about the sales visit charter or drug-specific safety scandals.

A detailing visit was considered as an actual training opportunity. It could play the role of a “ready-to-use training”, “one symptom, one solution!”. Interviewed GPs described meetings with sales reps as “a habit acquired at the hospital”. In comparison, all other training sources made available to practitioners were described as “time-consuming” and unsuited to their needs.

For some doctors, detailing visits were even considered essential: “Otherwise, who would inform you?” The diversity of available drugs seemed to create and maintain a feeling of dependence on the sales reps: “As soon as he’d gone, I felt so useless!”

The pharmaceutical industry’s persuasive force was described as belonging to a past era because current sales rep budget restrictions mean fewer reps and gifts: “There’s no more! There’s nothing left!”

Participants described both the “commercial” aspects of the rep visits and the strategies that could be used to deal with them: combining sources of information, limiting the number of sales reps, and choosing reliable contacts. These strategies seemed to give them a feeling of control: “When you increase your critical thinking, you’re well prepared to attend any training session, you are equipped to deal with promotions.”

Values

By values, we mean what is considered to be true, right, good, and a worthy goal to be reached, something to stand up for. The values identified as conducive to maintaining an ambivalent behavior towards sales reps were independence, courtesy and pragmatism.

Independence seemed to be a value very strongly held by the interviewed practitioners. This could have motivated them to accept detailing visits in order to distance themselves from any kind of authority that requires them to maintain a degree of independence towards sales reps: “I do what I want!”

Courtesy is the set of rules and good manners that govern behavior in society. It was very often referred to as a reason for receiving sales rep visits: “They’ve been waiting all day long,” “I always let them in; they’ve been waiting like everybody else!”

Pragmatism seems to lead some GPs to grant more importance to sales reps and the experience of fellow GPs than to information drawn from studies or recommendations.

Mechanisms involved in dealing with ambivalence

The data suggested significant sociological and psychological mechanisms that can help explain the reasons for the ambivalence of GPs towards the pharmaceutical industry: an experience-based rationale, self-efficacy and cognitive dissonance.

Experience-based rationale

To practitioners, empirical knowledge seemed more accessible and more real than scientific data. “What’s important to me is my results with my patients on a clinical and biological level […] After that, they can show me their studies, their gizmos; I couldn’t care less!” Within this context, the GPs downplayed the poor quality of information provided by sales reps and considered their own practical experience to be sufficient to confirm the effectiveness of and tolerance for new drugs. Sales reps seemed to cultivate this empirical view of medical expertise by using encouraging words such as “Try it and you’ll see!”. GPs’ preference for tangible information is well known and seems legitimate, but these results show that an experience-based rationale can sometimes take precedence over scientific rigor. This may contribute to practitioners’ acceptance of sales reps, as the relationship reinforces GPs’ confidence in their own practical experience. Representatives can therefore become the first link in the chain of information, despite their commercial role, since information can subsequently be verified in the field.

Self-efficacy

Several GPs declared being relatively inactive in the search for information about drugs, and claimed to feel unable to do so without detailing visits (“If the reps won’t talk about [drugs] with us, who will?”; “I can’t attend [Continuing Medical Education] as often as I’d like, so I’ll admit that I enjoy having reps come [to my door]”). This phenomenon can be analyzed through the concept of self-efficacy as described by psychologist Albert Bandura in 1977 [39]. Bandura defines self-efficacy as the sense a person has of their level of ability to achieve a given task. Without this feeling of self-efficacy, individuals tend to adopt a passive behavior, or even quit, while individuals who have a high sense of self-efficacy adopt a pro-active behavior. This well-known concept aligns with our observations in this study and could help explain why some GPs rely on detailing visits. Meeting pharma reps seems to act as a substitute for continuing medical education because of the GPs’ inability to use the complex and time-consuming scientific literature. This phenomenon seems to be compounded by the diversity of the pharmaceutical supply: “As for me, I’m absolutely unable to know the whole Vidal [a French drug database] by heart!” It could also be exacerbated by the fact that French GPs are often isolated and overworked [40].

Cognitive dissonance

Changes made to the interview guide because of GP defense mechanisms observed in the initial interviews reveal that the GP-rep relationship is somehow taboo. The word taboo is used here in its common sense which is to express any ban related to a fact or the mention of it, without being limited to spirituality or religion. This taboo aspect has appeared in previous research: when the Ipsos French Health Institute surveyed GPs about representative visits, the investigators also had to “disguise” the true motivation of their study because too many GPs refused to answer. [16] By avoiding any reference to sales rep visits, GPs deny the discrepancy between their actual behavior towards sales rep visits and their opinion of them, thus avoiding unpleasant situations as well as self-questioning (“I never said anything to anyone but I think that they’re starting to change their practices […] but I too was criticized […] when I followed training programs here, I was the only one to ask questions, I was the only one to criticize”). This “taboo” concept thus largely contributes to explain why so many GPs keep on receiving sales rep visits while expressing an unfavorable opinion about them. American psychologist Leon Festinger describes cognitive dissonance as the unpleasant tension that an individual feels when faced with two cognitions that are incompatible with each other (i.e., meeting sales reps and holding a negative opinion towards the pharmaceutical industry) [41]. In the presence of this tension, individuals use unconscious means to restore balance: by changing their behavior or changing their opinion. In a counter-intuitive manner, studies show that it is easier to modify one’s opinion than to change one’s behavior (for instance, after a failed attempt to stop smoking, smokers will tend to overstate the social benefits of smoking or to de-emphasize their will to stop) [41]. During the interviews, several GPs first expressed a very firm opinion towards sales reps: “We feel a bit like prey, [receiving a pharmaceutical representative] is never a trivial matter” or “Don’t count on the reps for information.” Their speech became much less strong as the interview went on: “Actually, when you increase your critical thinking, you’re well prepared to follow any training session.” An adjustment of the expressed opinion can be observed here that makes it more coherent with the behavior, which is to accept sales rep visits. This phenomenon can be observed within the framework of an interview but also within the framework of a whole career: “It used to be that I wasn’t very keen on reps. I was very cautious with them […] Anyway, it changed, it changed a lot.” The taboo surrounding detailing visits is also associated with a feeling of cognitive dissonance: avoiding the topic helps to avoid the emergence of discordance between opinion and behavior.

Discussion

The analysis of GPs’ motivations, perceptions and values revealed mechanisms that contribute to the understanding of the ambivalence between opinions and behaviors towards sales reps: cognitive dissonance, experience-based rationale and the use of sales reps as a substitute for scientific literature, which can be linked to a lack of self-efficacy. The GP-rep relationship can be considered as a part of a continuum: the GPs interviewed described meeting with sales reps as something mandatory during initial training. Therefore, meetings with sales reps can be considered as social learning and part of the hidden curriculum. Lempp and Seale defined the hidden curriculum as a set of influences that function at the level of the organizational structure and culture and that include, for example, implicit rules individuals must follow to survive in the institution, such as customs and rituals, as well as aspects taken for granted [42]. Six learning processes belonging to the hidden curriculum of medical schools have been identified: loss of idealism, adoption of a “ritualized” professional identity, emotional neutralization, change of ethical integrity, acceptance of hierarchy, and the learning of less formal aspects of “good doctoring.” Together they contribute to the enculturation of students as they become practitioners and members of the medical profession. Therefore, meetings with sales reps can be considered as a part of the hidden curriculum, which is maintained by the forces described above (practical reasons, substitute to training, cognitive dissonance, etc.).

The cognitive dissonance theory is well established and has been proven within the population at large but it has rarely been studied among GPs in France. This study brings new data suggesting that the mechanisms used to reduce cognitive dissonance may contribute to the GPs’ ambivalence. An American qualitative study published in 2007 suggested that GPs felt cognitive dissonance when meeting sales reps [43]. The authors described psychological processes of denial and rationalization used to reduce this state of cognitive dissonance: avoiding thinking about the conflicts of interests, denying the fact that the relations with pharmaceutical companies have an impact on GP behavior, denying their responsibility, itemizing techniques used to remain unbiased and claiming that meeting sales reps brought a benefit to patients. While this study was carried out in a cultural and societal context very different from the French one, the existence of another study identifying signs of cognitive dissonance brings external coherence to our own results.

Another qualitative study in 2007 in the USA explored the reasons why prescribers from various health professions continued to interact with pharma sales reps [44]. Most prescribers believed that overall sales rep interactions were beneficial to patient care and health practice. They either trusted the information provided by sales reps or felt that they were equipped to evaluate it independently. Despite acknowledgment of study findings to the contrary, prescribers stated that they were able to effectively manage interactions with reps such that their own prescribing was not adversely impacted. These data were consistent with our findings and interpretations.

In 2003, a British study explored the reasons why GPs received sales rep visits. Even though the societal context is very different from ours, [23] the similarities are startling. The British study revealed six major reasons for receiving sales rep visits and all of them were spontaneously cited by the GPs we interviewed. Some of their observations are surprisingly similar to ours: “Just because I have a pen with the name of a drug on it doesn’t mean I’m going to prescribe it” (England, 2003). “It’s not the pen that writes the prescription, it’s me!” (France, today). Or: “If it wasn’t for the drug reps, we’d be left high and dry” (England, 2003). “If the reps won’t talk about it with us, who will?” (France, today). The British study also revealed that sales reps fill the need for continuing medical education: “Vioxx, I did prescribe based on what I was being told by the rep. […] I did perceive that I had a particular need for a new alternative.” However, contrary to the results of the British study, French GPs did not use “neutral and legitimate” words to speak about detailing visits. Most of them seemed embarrassed to talk about it, suggesting a shift in perspective. The fact that “times have changed” was raised in every interview of French GPs confirms that sales reps are fewer than before, and receiving their visit is considered as less legitimate. Several French GPs said that sales reps were fewer and brought gifts less often. Other observational studies have arrived at the same conclusion [25, 45].

In contrast to a study published in 2018, [46] physicians talked relatively little about regulations and did not talk about drug-specific safety scandals such as those regarding rofecoxib (Vioxx) and benfluorex (Mediator). This difference is likely due to the interview guide, which sought to explore the reasons for the discordance between attitude and behavior and did not encourage these themes to emerge. Likewise, physicians did not talk about the Sales Visit Charter, suggesting that it remains relatively unknown more than 10 years after its adoption. Instead, they described a decrease in the frequency of medical visitors and in the size of the gifts offered to them. This decrease in the number and volume of gifts is confirmed by the analysis of the national “transparence-santé” database [45]. This decrease was used by doctors as an argument to trivialize the impact of sales rep visits on their practice. Although we can welcome the decrease in gifts, this trivialization may contribute to ongoing GP ambivalence towards sales visits.

Strengths and limitations

Participants were not asked for any feedback on the transcripts or the analysis because of the sensitive aspect of the research topic. Due to the ambivalence of the doctors on this subject, time was required in the interviews to build trust and to gain in-depth understanding. It was therefore decided to give priority to the depth of the interviews rather than to the number of interviews. The study’s design did not allow the authors to collect and incorporate data not known by the interviewed doctors, for instance the fact that in France GPs are quite isolated compared to Dutch ones [47]. This could have reinforced the feeling young doctors had of lacking knowledge and their need to rely on the information provided by the reps. Despite the method’s limits, this work is consistent with the exploratory goal. The impact of the personal values of the main investigator on the data collection process was controlled by a group identification of his preconceived cognitions and by training the investigator in semi-directive interview techniques. Their impact on the interpretive process was limited by a double analysis of every interview and by the diversity of approaches provided by the cross-disciplinary team. The fact that all the interviewed doctors were from the southeast of France could be considered a limitation, but our results are consistent with the literature which brings external coherence. Moreover, the concepts that emerged are universal and therefore likely to be transposed to other settings.

This work’s strength is that it is the very first exploratory study that seeks to understand the reasons why general practitioners are ambivalent towards sales reps in France. It is also of methodological and epistemological interest through the confluence of sociology, psychology and medicine. It could be useful for physicians, teachers and medical students to be aware of these results if they want to adopt a consciously chosen professional stance on pharma sales reps.

Conclusion

This work suggests three types of possible explanations to understand why some GPs receive sales rep visits while holding a negative opinion of them. The first is practical, such as to obtain information about new drugs, for convenience, and for social bonding. The second type of explanation is more social or cultural and is to remain within accepted codes of inter-personal relations and personal or professional characteristics (politeness, courtesy, welcoming the other person). When GPs lack confidence in their own experience and judgment capacities, when they experience personal or professional difficulties and are not active in searching for continuing education, sales reps are able to position themselves as information carriers. The third type of explanation concerns psychological factors such as cognitive dissonance, which is a well-established social psychology theory, and which helps understand how individuals whose behavior is not compatible with their opinions maintain a feeling of mental balance.

These observations lead us to consider the hypothesis that meetings with sales reps during initial training shape the GP-reps relationship which is then maintained over time by the three broad explanations described above. It has been demonstrated that the prohibition of gifts or samples has a positive influence on prescribing practices well over several years after students leave the university [48, 49]. These data bring external validity to our hypothesis. In 2017, Scheffer et al. ranked French medical universities according to their policy for managing conflicts of interest. At that time, the authors stated that French universities were behind a large number of countries, [50] despite some local initiatives and the willingness of French students to learn [21, 51].

Studies showed that this topic was still not adequately addressed by medical authorities, even though ten years have passed since the benfluorex scandal which led to a profound crisis in the French health sector [5254]. Some changes in the initial training could be introduced to incorporate our findings and previous suggestions: prohibiting professors from receiving gifts from sales reps, nudging them towards greater independence, providing a basic curriculum for all medical students, developing and supporting existing awareness actions for students and health professionals in France or elsewhere [21, 5558]. Continuing medical education could also be enhanced. GPs effectively felt the lack of free, non-biased and easy-to-access educational options that match their organizational constraints. French continuing medical education still suffers from a lack of independence and transparency in conferences and clinical practice guidelines despite the legal obligation for experts to disclose competing interests [44, 59]. The development of convenient, non-biased, and individual continuing medical education is therefore a public health necessity. Developing and valuing the independence of experts who speak at conferences and in learned societies is also necessary for the development of a culture of independence in health [2, 45, 60].

Previous studies raised the issue of inadequate application of the legislation in France, [7] which could explain why the GP-industry relationship is similar in France, Canada and the USA despite regulatory differences. In the French context, in which individual GPs are often overwhelmed by their working conditions and in which complex psychological factors are at work, GP-rep relationship issues may be more societal and political than individual.

Supporting information

S1 Checklist. COREQ checklist.

(PDF)

S1 Appendix. Interview guide.

(DOC)

Acknowledgments

First, the authors thank the study participants. They also thank the reviewers and the editor for valuable comments that helped to improve the manuscript, the Office of International Scientific Visibility, Université Côte d’Azur, for proofreading, Catherine Regent (PhD) for proofreading and editing, and Pr. Jean-Baptiste Sautron, (GP) Pr. Isabelle Milhabet (IM, psychologist), Pr Isabelle Feroni (IF, sociologist), Dr. Carol-Anne Boudy (GP), Dr. Nicolas Hogu (GP) and Kamel Tribeche (clinical psychologist) for their proofreading and their critical advice.

Abbreviations

GP

General Practitioner

USA

United States of America

Data Availability

No - some restrictions apply There are ethical restrictions on sharing relevant data as data contain potentially identifying and sensitive information. For data access requests, researchers may contact the departement d'enseignement et de recherche en médecine générale, 28 Avenue De Vallombrose, 06107 Nice, France via laura.bruley@univ-cotedazur.fr. Researchers may also contact the corresponding author with data access requests.

Funding Statement

The authors received no specific funding for this work.

References

  • 1.Pharmaceutical Research and Manufacturers of America. 2016 industry profile. Washington, DC: PhRMA, 2008. n.d. http://phrma-docs.phrma.org/sites/default/files/pdf/biopharmaceutical-industry-profile.pdf (accessed April 1, 2021).
  • 2.Moynihan R, Albarqouni L, Nangla C, Dunn AG, Lexchin J, Bero L. Financial ties between leaders of influential US professional medical associations and industry: cross sectional study. BMJ 2020:m1505. doi: 10.1136/bmj.m1505 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Hadland SE, Rivera-Aguirre A, Marshall BDL, Cerdá M. Association of Pharmaceutical Industry Marketing of Opioid Products With Mortality From Opioid-Related Overdoses. JAMA Netw Open 2019;2:e186007–e186007. doi: 10.1001/jamanetworkopen.2018.6007 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Inspection générale des Affaires Sociales. L’information Des Médecins Généralistes Sur Le Médicament. Paris: Inspection Générale des Affaires Sociales, septembre 2007, 247 f. Rapport n°RM2007-136P n.d. [Google Scholar]
  • 5.Mintzes B, Lexchin J, Sutherland JM, Beaulieu M-D, Wilkes MS, Durrieu G, et al. Pharmaceutical sales representatives and patient safety: a comparative prospective study of information quality in Canada, France and the United States. J Gen Intern Med 2013;28:1368–75. doi: 10.1007/s11606-013-2411-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.International Prescrire. “15 Years of Monitoring and One Sim- ple Conclusion: Don’t Expect Sales Representatives to Help Improve Healthcare Quality,”. La Revue Prescrire 15, no. 84 (2006): 154–159. n.d. [Google Scholar]
  • 7.Habibi R, Guénette L, Lexchin J, Reynolds E, Wiktorowicz M, Mintzes B. Regulating Information or Allowing Deception? Pharmaceutical Sales Visits in Canada, France, and the United States. J Law Med Ethics 2016;44:602–13. doi: 10.1177/1073110516684803 [DOI] [PubMed] [Google Scholar]
  • 8.Décret n° 2014–545 du 26 mai 2014 relatif aux procédures de contrôle de l’insuffisance professionnelle et aux règles de suspension temporaire des médecins, des chirurgiens-dentistes, des sages-femmes, des pharmaciens, des infirmiers, des masseurs-kinésithérapeutes et des pédicures-podologues—Légifrance n.d. https://www.legifrance.gouv.fr/loda/id/JORFTEXT000028990556/ (accessed May 8, 2021).
  • 9.World Health Organization/Health Action International. Understanding and responding to pharmaceutical promotion: a practical guide. 1st ed. 2009. [Google Scholar]
  • 10.Austad KE, Avorn J, Kesselheim AS. Medical students’ exposure to and attitudes about the pharmaceutical industry: a systematic review. PLoS Med 2011;8:e1001037. doi: 10.1371/journal.pmed.1001037 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Hermange M, Payet A. Les conditions de mise sur le marché et de suivi des medicaments-médicament: restaurer la confiance. Sénat-Comission des affaires sociales. 2006. n.d. http://www.senat.fr/notice-rapport/2005/r05-382-notice.html (accessed March 27, 2018). [Google Scholar]
  • 12.Guy-Coichard C, Perraud G, Chailleu A, Gaillac V, Scheffer P, Mintzes B. Inadequate conflict of interest policies at most French teaching hospitals: A survey and website analysis. PLoS ONE 2019;14:e0224193. doi: 10.1371/journal.pone.0224193 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Haute Autorité de Santé. Comprendre la promotion pharmaceutique et y répondre—un manuel pratique. 2009:181. [Google Scholar]
  • 14.Haute Autorité de Santé. Visite médicale: Accompagner les professionnels et les établissements. Haute Autorité de Santé n.d. https://www.has-sante.fr/jcms/c_1099657/fr/visite-medicale-accompagner-les-professionnels-et-les-etablissements (accessed May 7, 2021).
  • 15.Chaput H, Monziols M, Fressard L, Verger P, Ventelou B, Zaytseva A. More than 80% of general practitioners under 50 practice in a group. DRESS, 2019. n.d. [Google Scholar]
  • 16.Brocvielle AL., Idtaleb L (IPSOS Santé). Certification de la visite médicale. 2009:92. https://www.has-sante.fr/upload/docs/application/pdf/2009-10/enquete_has_ipsos_vm_032009.pdf (accessed May 10, 2021). n.d. [Google Scholar]
  • 17.Goupil B, Balusson F, Naudet F, Esvan M, Bastian B, Chapron A, et al. Association between gifts from pharmaceutical companies to French general practitioners and their drug prescribing patterns in 2016: retrospective study using the French Transparency in Healthcare and National Health Data System databases. BMJ 2019;367:l6015. doi: 10.1136/bmj.l6015 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Fickweiler F, Fickweiler W, Urbach E. Interactions between physicians and the pharmaceutical industry generally and sales representatives specifically and their association with physicians’ attitudes and prescribing habits: a systematic review. BMJ Open 2017;7:e016408. doi: 10.1136/bmjopen-2017-016408 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Physicians Wazana A. and the pharmaceutical industry: is a gift ever just a gift? JAMA 2000;283:373–80. doi: 10.1001/jama.283.3.373 [DOI] [PubMed] [Google Scholar]
  • 20.European Parliamentary Assembly. Public health and the interests of the pharmaceutical industry: how to guarantee the primacy of public health interests? 2015. http://semantic-pace.net/tools/pdf.aspx?doc=aHR0cDovL2Fzc2VtYmx5LmNvZS5pbnQvbncveG1sL1hSZWYvWDJILURXLWV4dHIuYXNwP2ZpbGVpZD0yMjAzMCZsYW5nPUVO&xsl=aHR0cDovL3NlbWFudGljcGFjZS5uZXQvWHNsdC9QZGYvWFJlZi1XRC1BVC1YTUwyUERGLnhzbA==&xsltparams=ZmlsZWlkPTIyMDMw (accessed April 1, 2021).
  • 21.Perraud G., Jouan R., Munck S, Barbaroux A., Promotion of critical thinking by and for students: Utopia or reality? The example of the Critical Thinking Days. Exercer 2021;175:328–34. n.d. [Google Scholar]
  • 22.Torgerson T, Wayant C, Cosgrove L, Akl EA, Checketts J, Re RD, et al. Ten years later: a review of the US 2009 institute of medicine report on conflicts of interest and solutions for further reform. BMJ Evidence-Based Medicine 2020. doi: 10.1136/bmjebm-2020-111503 [DOI] [PubMed] [Google Scholar]
  • 23.Prosser H, Walley T. Understanding why GPs see pharmaceutical representatives: a qualitative interview study. Br J Gen Pract 2003;53:305–11. [PMC free article] [PubMed] [Google Scholar]
  • 24.Vega A. Positivisme et dépendance: les usages socioculturels du médicament chez les médecins généralistes français. Sciences sociales et sante 2012;Vol. 30:71–102. [Google Scholar]
  • 25.Greffion J, Breda T. Façonner la prescription, influencer les médecins. Les effets difficilement saisissables du cœur de métier des grandes entreprises pharmaceutiques. Revue de la régulation Capitalisme, institutions, pouvoirs 2015. 10.4000/regulation.11272. [DOI] [Google Scholar]
  • 26.Lincoln YS, Guba EG. The Constructivist Credo. New York: Routledge; 2016. 10.4324/9781315418810. [DOI] [Google Scholar]
  • 27.Smith J. A, Flowers P, Larkin M. Interpretative phenomenological analysis: Theory, method and research. London: Sage; 2009. n.d. [Google Scholar]
  • 28.Van Manen M, Higgins I, Van Der Riet P. A conversation with Max van Manen on phenomenology in its original sense. Nurs Health Sci 2016;18:4–7. doi: 10.1111/nhs.12274 [DOI] [PubMed] [Google Scholar]
  • 29.Miles M, Huberman AM, Hlady-Rispal M. Analyse des données qualitatives. Bruxelles: De Boeck Université; 2007. [Google Scholar]
  • 30.Thomas DR. A general inductive approach for analysing qualitative evaluation data, American journal of evaluation, 27(2), 237–246 n.d. [Google Scholar]
  • 31.Oude-Endberink et al. The phenomeno-pragmatic analysis: a relevant method for qualitative research in health care. Exercer, 2013;105:4–11 n.d. [Google Scholar]
  • 32.Paulhus DL. Two-component models of socially desirable responding. Journal of Personality and Social Psychology 1984;46:598–609. 10.1037/0022-3514.46.3.598. [DOI] [Google Scholar]
  • 33.Rohrbasser A, Harris J, Mickan S, Tal K, Wong G. Quality circles for quality improvement in primary health care: Their origins, spread, effectiveness and lacunae- A scoping review. PLoS One 2018;13:e0202616. doi: 10.1371/journal.pone.0202616 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Article L1123-7—Code de la santé publique—Légifrance n.d. https://www.legifrance.gouv.fr/codes/article_lc/LEGIARTI000037825779/2019-06-01 (accessed May 10, 2021).
  • 35.Bardin L. L’ analyse de contenu. 5. éd. rev. et augm. Paris: Presses Univ. de France; 1989. [Google Scholar]
  • 36.Blanchet A, Gotman A. L’entretien. Paris: A. Colin; 2010. [Google Scholar]
  • 37.Kaufmann J-C. L’entretien compréhensif. Armand Colin; 2011. [Google Scholar]
  • 38.Beaud S, Weber F. Guide de l’enquête de terrain: produire et analyser des données ethnographiques. Paris: La Découverte; 2015. [Google Scholar]
  • 39.Bandura A. Self-efficacy: Toward a unifying theory of behavioral change. Psychological Review 1977;84:191–215. doi: 10.1037//0033-295x.84.2.191 [DOI] [PubMed] [Google Scholar]
  • 40.Dusmesnil Hélène et al., «Épuisement professionnel chez les médecins généralistes de ville: prévalence et déterminants», Santé Publique 4/ 2009. (Vol. 21), p. 355–364, n.d. [PubMed] [Google Scholar]
  • 41.Festinger L. A theory of cognitive dissonance. Reissued by Stanford Univ. Press in 1962, renewed 1985 by author, [Nachdr.]. Stanford: Stanford; Univ. Press; 2001. [Google Scholar]
  • 42.Lempp H, Seale C. The hidden curriculum in undergraduate medical education: qualitative study of medical students’ perceptions of teaching. BMJ 2004;329:770–3. doi: 10.1136/bmj.329.7469.770 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Chimonas S, Brennan TA, Rothman DJ. Physicians and drug representatives: exploring the dynamics of the relationship. J Gen Intern Med 2007;22:184–90. doi: 10.1007/s11606-006-0041-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Fischer MA, Keough ME, Baril JL, Saccoccio L, Mazor KM, Ladd E, et al. Prescribers and pharmaceutical representatives: why are we still meeting? J Gen Intern Med 2009;24:795–801. doi: 10.1007/s11606-009-0989-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Clinckemaillie M, Scanff A, Naudet F, Barbaroux A. Sunshine on KOL: a retrospective study about financial ties between medical key opinion leaders and pharmaceutical industry in France. MedRxiv 2021:2021.05.07.21255795. 10.1101/2021.05.07.21255795. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Reynolds E, Guénette L, Lexchin J, Cassels A, Wilkes MS, Durrieu G, et al. Reconciling a “pleasant exchange” with evidence of information bias: A three-country study on pharmaceutical sales visits in primary care. Health Policy 2018;122:250–5. doi: 10.1016/j.healthpol.2018.01.010 [DOI] [PubMed] [Google Scholar]
  • 47.Rosman S. Les pratiques de prescription des médecins généralistes. Une étude sociologique comparative entre la France et les Pays-Bas. Singuliers généralistes, Rennes: Presses de l’EHESP; 2010, p. 117–32. 10.3917/ehesp.bloy.2010.01.0117. [DOI] [Google Scholar]
  • 48.King M, Essick C, Bearman P, Ross JS. Medical school gift restriction policies and physician prescribing of newly marketed psychotropic medications: difference-in-differences analysis. BMJ 2013;346:f264–f264. doi: 10.1136/bmj.f264 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Larkin I, Ang D, Avorn J, Kesselheim AS. Restrictions On Pharmaceutical Detailing Reduced Off-Label Prescribing Of Antidepressants And Antipsychotics In Children. Health Affairs 2014;33:1014–23. doi: 10.1377/hlthaff.2013.0939 [DOI] [PubMed] [Google Scholar]
  • 50.Scheffer P, Guy-Coichard C, Outh-Gauer D, Calet-Froissart Z, Boursier M, Mintzes B, et al. Conflict of Interest Policies at French Medical Schools: Starting from the Bottom. PLoS ONE 2017;12:e0168258. doi: 10.1371/journal.pone.0168258 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Barbaroux A., Jedat V. Lifelong continuing education. Critical analysis of scientific and medical information. Management of links of interest. Exercer 2020;163:233–6. n.d. [Google Scholar]
  • 52.Mullard A. Mediator scandal rocks French medical community. Lancet 2011;377:890–2. doi: 10.1016/s0140-6736(11)60334-6 [DOI] [PubMed] [Google Scholar]
  • 53.Benkimoun P. New law introduces tougher rules on drug regulation in France. BMJ 2011;343:d8309. doi: 10.1136/bmj.d8309 [DOI] [PubMed] [Google Scholar]
  • 54.Fournier A, Zureik M. Estimate of deaths due to valvular insufficiency attributable to the use of benfluorex in France. Pharmacoepidemiol Drug Saf 2012;21:343–51. doi: 10.1002/pds.3213 [DOI] [PubMed] [Google Scholar]
  • 55.Scheffer P. Préparer les étudiants en médecine à affronter l’influence de l’industrie pharmaceutique: un enjeu éthique, professionnel et éducationnel. Pédagogie Médicale 2016;17:189–97. 10.1051/pmed/2017001. [DOI] [Google Scholar]
  • 56.Scheffer P. Quelle formation à l’indépendance est-elle possible pour les étudiants en médecine, par rapport à l’influence de l’industrie pharmaceutique? Thèse de sciences de l’éducation. Université Paris 8, 2017. [Google Scholar]
  • 57.Cauchon M, Labrecque M, Baillargeon L, Légaré F, Frémont P. Site Modules d’auto-apprentissage des habiletés de lecture critique et de gestion de l’information n.d. http://infocritique.fmed.ulaval.ca (accessed April 1, 2021). [Google Scholar]
  • 58.Romero M. Design of a training course for critical analysis of pharmaceutical promotion integrated in the general practice course: the FACRIPP. Exercer 2019;157:422–3 n.d. [Google Scholar]
  • 59.Lenzer J. French guidelines are withdrawn after court finds potential bias among authors. BMJ 2011;342:d4007–d4007. doi: 10.1136/bmj.d4007 [DOI] [PubMed] [Google Scholar]
  • 60.Barbaroux A, Lardy G. Sunshine on CMGF: Étude observationnelle des déclarations de liens d’intérêts au Congrès de la Médecine Générale France et liens d’intérêts des médecins intervenants. Therapies. 2021;10. doi: 10.1016/j.therap.2021.09.004 [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Barbara Mintzes

23 Mar 2021

PONE-D-21-04814

GPs and pharma reps: why are we so ambivalent?

Crossing perspectives from sociology, psychology and general practice toward a qualitative study in France.

PLOS ONE

Dear Dr. Barbaroux,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

This article addresses an important issue, the relationship between primary care physicians and pharmaceutical sales representatives. The discussion is thoughtful and the focus on cognitive dissonance resonates with other related research. Currently, inadequate information is provided on methods (selection of participants, study conduct, and approach to analysis) to adequately assess the article's contribution to the existing literature on this issue. Additionally, the added French context needs to be considered, as is outlined below, given the extra restrictions on sales visits in France as compared with most countries. This was a key theme emerging in a previous qualitative study (Reynolds et al. 2018 - full ref below). As is noted below, given that three case scenarios with very different questioning afterwards were included in this study, reporting on how doctors responded to these scenarios and links to their views on sales visits need to be made more explicit. This is likely a valuable component of the study data and it is unclear why it was omitted from results reporting. Additionally, I had concerns about adequacy of assessment of data saturation with 3 different scenarios & questioning and 10 interviews in total. You may want to reconsider whether additional data are needed as well as a re-analysis. Here are my detailed recommendations:

  1. Clarification of methods and ensuring that there is an explicit link between how methods are described and how the analysis is conducted and results reported and discussed. Dr Grundy describes this in detail in her comments, specifically in relation to the theoretical framing of the study and both the need for a more explicit description in the methods, with citations, and a clearer link between this framework and how results are analysed and presented. In addition the approach to selection of study participants (convenience, snowball, purposive?), how many were contacted and agreed or refused needs to be reported in greater detail? Were there specific inclusion criteria (for example that the interviewed GPs saw reps regularly)? If the aim was to explore effects of specific factors linked to demographics, for example gender differences, it’s unclear why only 2 female GPs were included, given a 44% female GP workforce in France, and also whether differences by demographics (age, gender) and number of years in practice or type of practice were considered as factors in assessment of whether saturation had been reached. It is also unclear when the interviews were carried out. This needs to be stated directly.

  1. How the case scenarios informed the discussion and interpretation of results needs to be better reported. A study strength is the piloting of the approach used to questioning, and the introduction of revisions to avoid a social desirability bias and/or defensive responses to questioning. As these are two separate However, it is unclear how the three case scenarios were incorporated into this study, especially given the fundamental differences in approach to questioning following each scenario. The description of these scenarios in the article remains general and does not highlight these differences, nor include even a brief description of the drug and context per scenario. Were the specific drugs selected based on lack of evidence of therapeutic advantages or cost-effectiveness ratings? How did doctors respond to the specific scenarios? And were there any clear links between their responses and attitudes and experiences towards sales representatives? It is also unclear how these scenarios functioned in practice – did all of the doctors spontaneously mention sales representatives in response to these scenarios on a new drug prescription, or did they mention other factors more often and researchers introduced the link to sales representatives? Additionally, why were three separate scenarios used with different associated questions – some more directly related to sales representatives than others - and how often was each one used? When data saturation was being considered, how did the use of multiple scenarios affect judgments of thematic saturation?   

  1. The study could be much better informed by the unique position of GPs in France in relation to reps as compared with most other countries, in that free medication samples and gifts of food and drink within the office are not allowed, and an attempt has been made to ensure information quality through public oversight of a certification procedure. Additionally, La Revue Prescrire used a network of GPs to analyse the content of sales visits in France over a 15-year period. (La Revue Prescrire 2006; 26(272):383-389) The context and French policies such as the sales visit charter would be expected to have some influence. How was the approach to questioning and analysis informed by this context? Also please include a description of the current approach to oversight. See for example: https://www.has-sante.fr/jcms/c_1099657/fr/visite-medicale-accompagner-les-professionnels-et-les-etablissements; Habibi et al. Journal of Law, Medicine and Ethics. 2016; 44: 602-613; Reynolds et al. Health Policy 2018; 122(3): 250-255; Mintzes et al. JGIM 2013; 28(10): 1368–1375. In the focus groups described in Reynolds et al., we also found that a strong influence from the Mediator scandal in how the French GPs discussed sales rep visits. This is likely to have been influenced by timing of the focus groups but an open question is whether in the current interview study there was any spontaneous discussion of safety concerns and/or of Mediator.

  1. As noted by Dr Lexchin, editing of the manuscript by an English-language editor would be helpful. There are a few repeated “false friends”. For example ‘laboratoires’ translates to pharmaceutical companies, not to labs. In English a laboratory or lab is a facility where scientific experiments of all types take place. A ‘lab scientist’ is someone using usually very expensive specialised equipment (in their lab) to carry out scientific experiments.

Please submit your revised manuscript by June 1, 2021. If you will need more time than this to complete your revisions (for example if additional data collection is needed), please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Barbara Mintzes

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please consider changing the title so as to meet our title format requirement (https://journals.plos.org/plosone/s/submission-guidelines). In particular, the title should be "Specific, descriptive, concise, and comprehensible to readers outside the field" and in this case it could be preferable to avoid undefined acronyms

3.  We suggest you thoroughly copyedit your manuscript for language usage, spelling, and grammar. If you do not know anyone who can help you do this, you may wish to consider employing a professional scientific editing service.  

Whilst you may use any professional scientific editing service of your choice, PLOS has partnered with both American Journal Experts (AJE) and Editage to provide discounted services to PLOS authors. Both organizations have experience helping authors meet PLOS guidelines and can provide language editing, translation, manuscript formatting, and figure formatting to ensure your manuscript meets our submission guidelines. To take advantage of our partnership with AJE, visit the AJE website (http://learn.aje.com/plos/) for a 15% discount off AJE services. To take advantage of our partnership with Editage, visit the Editage website (www.editage.com) and enter referral code PLOSEDIT for a 15% discount off Editage services.  If the PLOS editorial team finds any language issues in text that either AJE or Editage has edited, the service provider will re-edit the text for free.

Upon resubmission, please provide the following:

a) The name of the colleague or the details of the professional service that edited your manuscript

b) A copy of your manuscript showing your changes by either highlighting them or using track changes (uploaded as a *supporting information* file)

c) A clean copy of the edited manuscript (uploaded as the new *manuscript* file)

4. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For more information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

5.  Thank you for stating the following financial disclosure:

"NO - The funders had no role in study design, data collection and analysis, decision to

publish, or preparation of the manuscript."

At this time, please address the following queries:

  1. Please clarify the sources of funding (financial or material support) for your study. List the grants or organizations that supported your study, including funding received from your institution.

  2. State what role the funders took in the study. If the funders had no role in your study, please state: “The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

  3. If any authors received a salary from any of your funders, please state which authors and which funders.

  4. If you did not receive any funding for this study, please state: “The authors received no specific funding for this work.”

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

6. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please delete it from any other section.

7. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: No

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: N/A

Reviewer #3: N/A

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: No

Reviewer #2: Yes

Reviewer #3: No

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

Reviewer #2: Yes

Reviewer #3: No

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: This is a qualitative study looking at why French GPs see sales representatives even though they generally have negative attitudes about the pharmaceutical industry. This type of inquiry is useful in formulating strategies about how to minimize the contact between these two groups and as such the authors should put forward policies towards that end based on their research.

1. The English in many places is awkward and the entire manuscript should be copy edited by someone who has English as a first language.

2. It would help in commenting on the manuscript if the lines were numbered.

3. In describing how interactions with sales representatives influence prescribing the authors should cite some of the literature coming out of the use of the Open Payments database.

4. Page 4: I think that it's highly likely that a portion of the medical profession is familiar with the terms cognitive dissonance and hidden curriculum and this sentence should be modified so as not to imply that it applies to the entire profession.

5. Page 4: The part of the sentence "complete the latter in a liberal field" is not clear.

6. Page 5: The authors should give a bit of background about general practice in France - how are doctors paid, do they generally practice alone or in groups, is there any funding for continuing medical education, do they also work in hospitals, etc.

7. Page 5: USA should be spelled out in full the first time it is used.

8. Page 5: The regulation of the activities of pharmaceutical representatives should be briefly described along with any penalties for violating the regulations.

9. Page 5: In what ways does the industry take part in the training of GPs?

10. Page 6: The authors should cite some of the literature showing that GPs believe in their own ability to resist being influenced by representatives but not necessarily in the ability of other GPs.

11. Page 6: There should be a reference to the literature describing the phenomenological approach.

12. Page 7: The existing literature used to generate the interview guide should be cited.

13. Page 7: What GP details are the authors referring to? The city where the study took place is mentioned later but should be mentioned here. How did the authors determine if the GPs saw sales representatives? Did all GPs invited agree and if not how many refused?

14. Page 9: I'm not sure how to interpret the final sentence in the Methods section.

15. Page 9: How does peer group continuing education function in France?

16. Page 10 (Table 1): What does "setting as a team" mean in the French context?

17. Page 10 (last paragraph): The first sentence is a repeat of what was said in the Introduction and Methods and should be deleted.

18. Page 11: What does "counter-phobic effect" mean?

19. Page 12: What does “training session” mean?

20. Page 15: The part of this paragraph starting "Thus, these data..." is a conclusion and belongs in that section.

21. Page 17: What “tendency” are the authors talking about?

22. Page 19: AMSA stopped publishing rankings in 2016.

Reviewer #2: Dear authors,

Thank you first for this interesting and useful work. I used the Côté-Turgeon assessment grid (https://www.pedagogie-medicale.org/articles/pmed/abs/2002/02/pmed20023p81/pmed20023p81.html )

to evaluate your article and all the points listed got a yes, there are so only minor corrections to do according to me.

1) I would rephrase this extract like following :

Many studies show a correlation between receiving a gift from pharma reps or meeting them

and an amount of bigger, more expensive and sometimes less rational prescriptions [give here the corresponding references, this one should belong to them I think: https://bmjopen.bmj.com/content/7/9/e016408 ]. A recent study published in the BMJ confirmed this for French GPs through indicators such as prescription of antibiotics, benzodiazepines and vasodilators [4]

2) This situation is as much of a problem on the financial level (with costs that are indirectly born by the community via medication prices) as it is on the social, ethical and Public Health levels. [2]

You could add this more recent reference here : Public health and the interests of the pharmaceutical industry: how to guarantee the primacy of public health interests? European Parliamentary Assembly, 2015 : http://semantic-pace.net/tools/pdf.aspx?doc=aHR0cDovL2Fzc2VtYmx5LmNvZS5pbnQvbncveG1sL1hSZWYvWDJILURXLWV4dHIuYXNwP2ZpbGVpZD0yMjAzMCZsYW5nPUVO&xsl=aHR0cDovL3NlbWFudGljcGFjZS5uZXQvWHNsdC9QZGYvWFJlZi1XRC1BVC1YTUwyUERGLnhzbA==&xsltparams=ZmlsZWlkPTIyMDMw

3) Therefore, while the role of industry in therapeutics and innovation is indisputable, must be encouraged and supported, the interest in the independence of prescribers is essential.

I disagree with this sentence, which for me corresponds more to the narrative of the pharmaceutical firms which wants to give themselves the best parts than facts. Prescrire showed that very few true innovative drugs have come to the markets in the last decades (Between 2002 and 2016, 52% of new drugs brought nothing new, 1% a real breakthrough, 6% an advantage, and 15% were not acceptable : Prescrire.

Feb 2017; 37 (400) : 133).

There are other arguments for this point that I presented in my PhD thesis (pages 24 o 31 : https://formindep.fr/these-de-paul-scheffer/) and people like Marcia Angell, former editor in chief of the NEJM, argues at the end of her book the pharmaceutical firms should not participate to the research and the education in medicine and shoud rather concentrate their action only making the drugs available everywhere they are needed (The Truth about Drug Companies).

At last, there are numerous calls for giving more public financial support to the public medical research, which seems to be much better than supporting firms, with some exemples given in this BMJ 2019 article https://www.bmj.com/content/367/bmj.l6576)

You may simply put it this way : Therefore the interest in the independence

of prescribers remains an essential goal, ten years after the publication of the Institute of Medicine report Conflicts of Interest in Medical

Research, Practice, and Education (you could here use this recent reference : https://ebm.bmj.com/content/early/2020/11/11/bmjebm-2020-111503)

4) However, their behavior remains rather positive towards

medical industries, as they still predominantly receive pharmaceutical representatives (80% of practitioners in France). [7, 8]

Here you could use this more recent reference instead, which gives the same number : https://journals.openedition.org/regulation/11272. I encourage the authors to read the whole paper to see if they are other elements that they would use for their article.

5) No study exploring the determining factors of such a contradiction has been found in France.

I don’t agree totally with this sentence because there is at least one work adressing this issue, although not specifically, whih is this article by the health anthropologist Anne Vega : https://www.cairn.info/revue-sciences-sociales-et-sante-2012-3-page-71.htm

I think to these two extracts of this document :

Enfin, les représentants des firmes sont aux côtés des étudiants dès la faculté [20][20]L’ensemble de ces constats (développés dans Vega, 2011b) sont à…, ce qui les habitue ensuite à une présence jugée naturelle, peu « chronophage » et/ou aidante

Si les enquêtés font plutôt confiance à l’expertise des médecins spécialistes, c’est par manque de moyens de contrôle sur leurs prescriptions, mais aussi parce qu’ils accordent une valeur plus faible à leurs propres savoirs et à leurs expériences généralistes, le plus souvent jugés peu scientifiques [28][28]Souligné aussi par Bloy (2008).. Cette dévalorisation contribue également à limiter le partage de décisions avec les confrères généralistes, expliquant des difficultés observées à centraliser les dossiers de patients. Elle expliquerait surtout des recours privilégiés, voire exclusifs, aux avis et aux médicaments prescrits par les médecins spécialistes, ou vantés comme tels par les représentants des firmes pharmaceutiques. Les savoirs spécialisés ou experts restent en effet des gages d’assurance et de prestige, voire les seules références, chez de jeunes médecins. Ainsi, des enquêtés ont le sentiment de « ne rien savoir » au sortir des facultés et sont constamment à la recherche de « recettes ». Non seulement ils reproduisent des prescriptions spécialisées, mais ils ajoutent à leur propre panel de médicaments des produits spécialisés.

According to this, a formulation like the following one may be more accurate :

One qualitative study gave some elements of comprehension of the the French GPs’ interactions with pharmaceutical sales representatives, like …, but no one tried to understand the contradiction why some general practitioners do receive the

visits of pharmaceutical representatives while they convey a rather negative opinion towards

pharmaceutical industries.

6) Several GPs in our sample have mentioned that pharmaceutical representatives and their bringing gifts are now less numerous.

Jerôme Greffion arrived at the same finding, you could mention it : https://journals.openedition.org/regulation/11272

7) You mention that among the interviewed GPs, one decided not to receive the reps anymore. Like Côté and Turgeon say (https://www.pedagogie-medicale.org/articles/pmed/abs/2002/02/pmed20023p81/pmed20023p81.html ), the deviant opinions are always very interesting to notice. Could he give some other reasons not mentioned by the others ?

8) About Limitations :

One limitation that could be added is the fact that the study, by its design, would not be able to collect elements of understanding 1) that would not be known by the interviewed doctors, for instance the fact that in France GP are quite isolated compared to the Dutch ones (see https://www.cairn.info/singuliers-generalistes--9782810900213-page-117.htm), which would reinforce the feeling of young doctors not to know and to rely on the information given by the reps. An other element conducting to the same result could be the fact that French medical students integrate the idea that they don’t have the right not to know during their training (see https://formindep.fr/these-de-paul-scheffer/ pages 177 to 181 and https://journals.openedition.org/ethiquepublique/1818), or 2) that they don’t want to speak about, linked to the fact that this topic is rather taboo.

9) This hypothesis has an external validity since some universities in the USA banned detailing visits

That is not exactly correct :

A growing number of US hospitals and academic medical centers (AMCs) have guidelines that limit interactions between physicians and pharmaceutical sales representatives. 1 No AMC has completely banned detailing, or the promoting of drugs directly to physicians by pharmaceutical salespeople. However, some AMCs have limited detailing visits—for instance, by restricting visiting hours or locations. Another strategy employed by AMCs is to ban physicians from receiving gifts or sample products from sales representatives (https://www.healthaffairs.org/doi/10.1377/hlthaff.2013.0939)

10) In 2017, Scheffer et Al. ranked French medical universities and teaching

hospitals according to their management policy for interest conflicts.

The study about teaching hospitals was published in 2019, not 2017.

11) The authors states that French universities are behind a lot of countries, including the USA, despite French students willingness to learn [23-26]. Indeed, the American Medical Student Association (AMSA) has been publishing a yearly ranking of American universities since 2007, with much better results.

This is not true anymore today, if we would use the AMSA score card type, all French medical schools which voted the Deans’ Conference of medicine ethical charter of 2017 would receive a A.

A formulation like this would be more accurate according to me :

Both studies showed that this topic was not adequately adressed by medical authorities yet, in spite of the ten years that have passed since the benfluorex scandal which led to a profound crisis in the French health sector. (suggested references : Mullard A (2011) Mediator scandal rocks French medical community. Lancet, 377: 890–892. pmid:21409784. Benkimoun P (2011) New law introduces tougher rules on drug regulation in France. BMJ 343: d8309. pmid:22194407. Fournier A, Zureik M. (2012) Estimate of deaths due to valvular insufficiency attributable to the use of benfluorex in France. Pharmacoepidemiol Drug Safety, 21: 343–351. Loi n° 2016–41 du 26 janvier 2016 de modernisation du système de santé français ). Some changes in the initial training could be fostered including our findings and precedent suggestions (https://www.pedagogie-medicale.org/articles/pmed/abs/2016/04/pmed170001/pmed170001.html)

Reviewer #3: The authors conducted a qualitative, phenomenological study to understand better why GPs in France continue to see pharmaceutical representatives while maintaining a critical view of the pharmaceutical industry. This is an important topic, but is one that has been previously explored (Chimonas et al, 2009, Fischer et al, 2008, Prosser 2008).

One of the key markers of rigour in qualitative research is “congruency” – that is, that the research aims and question are grounded in the theoretical orientation of the researchers (ontology, epistemology, e.g. socially constructed knowledge), which is consistent with the methodology (e.g. interpretive phenomenology) and methods (e.g. interviews) selected. Within this project, there are frequently mismatches that threaten the congruency of this work and introduce threats to the quality of the research.

Specifically, the researchers point to different disciplinary perspectives (“psychology, sociology and general practice”) as their theoretical grounding, but do not specify what these are or, how they worked together.

The researchers in the methods section, state that they used “interpretive phenomenology” but it is unclear in which tradition (citations are missing) and the tenets of this approach are not explicitly stated.

The methods chosen for sampling, interviewing and data analysis do not seem to be related to interpretive phenomenology (which emphasises narratives, observations, and action over reflection). The relationship between the methods, the methodology and the theoretical perspectives needs to at minimum, be explicit.

Finally, the researchers continue to mention “interpretive bias” in the methods and discussion and ways to mitigate this, however, the concept of “bias” is inconsistent with a qualitative, interpretive approach. Instead, the researchers should apply criteria for rigour that reflect research methods that emphasise the researcher’s role in data collection and analysis and that knowledge is socially constructed.

It appears the sample is a convenience rather than purposive sample. Sampling could be strengthened if individuals were recruited based on theoretically informed (rather than merely demographic) criteria. The researchers mention data saturation as a criterion for sampling; however, they do not demonstrate how they knew saturation was achieved and there does not seem to be sufficient presentation of the range of this phenomenon to suggest that they sampled the full range of this experience. This is not a critique of the sample size, but rather, that qualitative researchers must demonstrate to the reader that they sought contrasting perspectives and individuals with diverse experience until no new information arose.

The researchers stated that this is an ‘exploratory’ analysis, but also seem to try and theorize this phenomenon. Thus, the aims of this work need clarification. If this is more of a theoretical analysis (around hidden curriculum, or cognitive dissonance, e.g. which I think would be of high value), then the theoretical perspectives informing this work and past work on this topic should be brought up front to really highlight what this work adds. At the moment, it is unclear which literature this work is in conversation with and the discussion really contains a lot of useful analysis, but fails to put it into context.

At the moment, the analysis remains description, but could be greatly strengthened by incorporating the material in the discussion. The researchers should clarify whether they are applying particular theoretical perspectives, or are conducting a grounded, interpretive analysis (per the stated interpretive phenomenology), and then work to refine the results in either direction.

This work is important and I encourage the researchers to continue this work. However, I think it may need to be reworked from the start to really clarify the aim, the theory/methods package, and to re-analyse the findings in this vein.

This work is important and I encourage the researchers to continue this work. However, I think it may need to be reworked from the start to really clarify the aim, the theory/methods package, and to re-analyse the findings in this vein.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Joel Lexchin

Reviewer #2: Yes: Paul Scheffer

Reviewer #3: Yes: Quinn Grundy, University of Toronto

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2022 Jan 24;17(1):e0261661. doi: 10.1371/journal.pone.0261661.r002

Author response to Decision Letter 0


31 May 2021

Answers to reviewers:

Dear Barbara Mintzes, Academic Editor,

Dear Joel Lexchin, Paul Scheffer and Quinn Grundy, reviewers,

Thank you for giving us the opportunity to upgrade our manuscript. We have considered all your comments with interest. Please find below our point-by-point answer.

Academic Editor reports:

This article addresses an important issue, the relationship between primary care physicians and pharmaceutical sales representatives. The discussion is thoughtful and the focus on cognitive dissonance resonates with other related research. Currently, inadequate information is provided on methods (selection of participants, study conduct, and approach to analysis) to adequately assess the article's contribution to the existing literature on this issue.

Thank you. The methods section has been clarified (see below).

Additionally, the added French context needs to be considered, as is outlined below, given the extra restrictions on sales visits in France as compared with most countries. This was a key theme emerging in a previous qualitative study (Reynolds et al. 2018 - full ref below).

Thank you for the additional reference that was added to ours. The French context is now described in detail in the introduction (lines 137-161). In the discussion – comparison with other studies, a sentence has been added : “In contrast to a study published in 2018,[44] physicians talked relatively little about regulations and did not talk about drug-specific safety scandals such as those regarding rofecoxib (Vioxx) and benfluorex (Mediator). This difference is likely due to the interview guide, which sought to explore the reasons for the discordance between attitude and behavior and did not allow these themes to emerge. Likewise, physicians did not talk about the sales visit charter, suggesting that it remains relatively unknown more than 10 years after its adoption. Instead, they described a decrease in the frequency of medical visitors and in the size of the gifts offered to them. This decrease in the number and volume of gifts is confirmed by the analysis of the national “transparence-santé” database.[43] This decrease was used by doctors as an argument to trivialize the impact of sales rep visits on their practice. Although we can welcome the decrease in gifts, this trivialization may contribute to ongoing GP ambivalence towards sales visits.”

As is noted below, given that three case scenarios with very different questioning afterwards were included in this study, reporting on how doctors responded to these scenarios and links to their views on sales visits need to be made more explicit. This is likely a valuable component of the study data and it is unclear why it was omitted from results reporting.

The scenarios served to gradually bring up the issue of sales visits without triggering the reluctance and social desirability bias observed in the two preliminary interviews. The questions that followed the three scenarios were similar. The number of scenarios only served to renew the discussion if necessary, by moving on to the next scenario. […] The three scenarios did not each provide a different pattern of responses, which was expected since the research question was not at all about the drugs discussed in the scenarios, but about the doctor-sales rep relationship. This clarification was made in the introduction (line 259) and the results.

Additionally, I had concerns about adequacy of assessment of data saturation with 3 different scenarios & questioning and 10 interviews in total. You may want to reconsider whether additional data are needed as well as a re-analysis.

Thank you for this comment. Each physician responded to all three scenarios, which explains how we reached data saturation with 10 interviews. We have clarified this point in the methods section.

Here are my detailed recommendations: Clarification of methods and ensuring that there is an explicit link between how methods are described and how the analysis is conducted and results reported and discussed. Dr Grundy describes this in detail in her comments, specifically in relation to the theoretical framing of the study and both the need for a more explicit description in the methods, with citations, and a clearer link between this framework and how results are analyzed and presented.

Thank you. Each of Dr. Grundy's comments has been carefully considered. I have not copied every comment here so as not to lengthen the document, please see below.

In addition the approach to selection of study participants (convenience, snowball, purposive?)

“A convenience sampling method was used to select people with a range of experience in meeting sales reps. No specific inclusion or non-inclusion criteria were imposed since the research team considered that any GP could contribute new data to explain the phenomenon studied. The selection of practitioners was based on variation criteria for the following characteristics: …”

how many were contacted and agreed or refused needs to be reported in greater detail?

Done: “Ten GPs refused to participate because of lack of time.”

Were there specific inclusion criteria (for example that the interviewed GPs saw reps regularly)?

Added: “No specific inclusion or non-inclusion criteria were imposed since the research team considered that any GP could contribute new data to explain the phenomenon studied.”

If the aim was to explore effects of specific factors linked to demographics, for example gender differences, it’s unclear why only 2 female GPs were included, given a 44% female GP workforce in France, and also whether differences by demographics (age, gender) and number of years in practice or type of practice were considered as factors in assessment of whether saturation had been reached.

The aim was not to explore the effects of specific factors linked to demographics but to gather a wide range of GPs without missing any demographic criteria. We added in the methods section, line 220 “The purpose of a phenomenological approach is mainly to shed light on the essence of a person’s experience in relation to a specific phenomenon, in this instance meeting sales reps despite holding a negative opinion of them. In a phenomenological study, sample sizes are typically small because data saturation is not essential if the objective is to understand the meaning individuals give to their own lived experience. (Van Manen et al, 2016).

It is also unclear when the interviews were carried out. This needs to be stated directly.

This is stated at the beginning of the results section: “The material is composed of 10 interviews carried out from April to December 2014, of an average duration of 50 minutes (median of 46 minutes), for a total duration of 8 hours and 22 minutes, representing 118 pages of transcriptions”.

How the case scenarios informed the discussion and interpretation of results needs to be better reported. A study strength is the piloting of the approach used to questioning, and the introduction of revisions to avoid a social desirability bias and/or defensive responses to questioning. As these are two separate However, it is unclear how the three case scenarios were incorporated into this study, especially given the fundamental differences in approach to questioning following each scenario. The description of these scenarios in the article remains general and does not highlight these differences, nor include even a brief description of the drug and context per scenario.

I apologize for the lack of precision in the way the interview guide was described. In fact, the questions following each scenario were similar. Once again, the number of scenarios was only meant to renew the discussion when necessary, within a different context. The interview guide (supplementary materials) has been modified to be more explicit and the description of the scenarios has been enhanced :

“The scenarios served to gradually bring up the issue of sales rep visits without causing the reluctance and social desirability bias observed in the two preliminary interviews. The questions that followed the three scenarios were similar (“What sources of information do you regularly use?” – “Can you tell me more about sales reps?”). The next questions aimed at progressively focusing on the GP/rep relation (“Have you ever considered no longer meeting reps?” – “I am particularly interested in the apparent contradiction between what you tell me” ... “and, at the same time,” ... “How did you come to this opinion?”). Some questions were not directly related to sales reps in order to avoid defensive reactions observed in the preliminary interviews. The second and the third scenarios only served to renew the discussion when necessary by moving on to the next scenario. The first scenario concerned the prescription of sitagliptin to a frail patient, the second the switch to oral anticoagulation in an elderly and poly-medicated patient and the third the prescription of rivaroxaban to a young patient with paraphlebitis, following the advice of a colleague.”

Were the specific drugs selected based on lack of evidence of therapeutic advantages or cost-effectiveness ratings?

Yes. The specific drugs were selected based on lack of evidence of therapeutic advantages or cost effectiveness because previous studies have shown that it is in a situation of doubt that a practitioner is the most sensitive to the influence of pharmaceutical representatives.

How did doctors respond to the specific scenarios?

The aim of the scenarios was not to collect different answers and analyze them separately but to allow the discussion to go deeper during the interview.

And were there any clear links between their responses and attitudes and experiences towards sales representatives?

We did not question GPs further about what they thought about the scenarios, the discussion quickly turned to their relationship with pharma sales reps.

It is also unclear how these scenarios functioned in practice – did all of the doctors spontaneously mention sales representatives in response to these scenarios on a new drug prescription, or did they mention other factors more often and researchers introduced the link to sales representatives?

All GPs but one spontaneously mentioned sales reps following the scenarios. When the physician did not address the visit spontaneously, the interviewer addressed it specifically (added in the results section).

Additionally, why were three separate scenarios used with different associated questions – some more directly related to sales representatives than others - and how often was each one used?

Some questions were not directly related to sales reps in order to avoid defensive reactions observed in the preliminary interviews (added in the methods section).

All questions were used for all GPs (added in the interview guide).

When data saturation was being considered, how did the use of multiple scenarios affect judgments of thematic saturation?

Since all scenarios were used for all interviewed GPs, the use of multiple scenarios did not affect judgments of thematic saturation.

The study could be much better informed by the unique position of GPs in France in relation to reps as compared with most other countries, in that free medication samples and gifts of food and drink within the office are not allowed, and an attempt has been made to ensure information quality through public oversight of a certification procedure.

Added in the introduction: “The role of pharmaceutical sales representatives (sales reps) is regulated by the government through a Sales Visit Charter and a certification procedure but despite more stringent regulatory requirements than in North America, the information provided by sales reps remains poor.[5,6] The Sales Visit Charter Promotes good practices such as the presentation of approved product information including side effects and contraindications. Despite strict regulations (health authorities can impose fines of up to €10,000 or 10% of a product’s annual sales revenues) [7], the Sales Visit Charter is rarely respected.[5,6] Pharma sales reps are not allowed to follow continuing medical education courses. A national fund for continuing medical education finances free courses for GPs and compensates for the loss of three days’ worth of medical fees while training. This non-biased continuing medical education is mandatory.[8] Initial and continuing medical education are supposed to be provided by impartial experts but these experts can be opinion leaders with financial ties to the industry.[9–12] Despite these measures, the pharmaceutical industry still plays an active role in research and in general practitioner (GP) training from the preclinical years to continuing medical education.[11] The French National Health Authority, “Haute Autorité de Santé” (HAS), encourages professionals and healthcare facilities to address the issue of sales visits and provides tools such as a French translation of the World Health Organization’s guide “Understanding and responding to pharmaceutical promotion: a practical guide”. HAS also provides guidance to health care facilities on how to regulate sales visits.[13,14] […] Free drug samples and gifts of food and drink in the office are not allowed in France, but GPs still receive gifts and invitations to restaurants since the law allows for exceptions.”

Additionally, La Revue Prescrire used a network of GPs to analyse the content of sales visits in France over a 15-year period. (La Revue Prescrire 2006; 26(272):383-389) The context and French policies such as the sales visit charter would be expected to have some influence. How was the approach to questioning and analysis informed by this context?

Thank you for this reference to La Revue Prescrire, this work is very interesting and has been added to our references (in the introduction and the discussion). In our study, physicians did not talk about the sales visit charter, suggesting that it remains relatively unknown more than 10 years after it was adopted. Instead, they described a decrease in the frequency of sales rep visits and in the size of the gifts offered to them. This decrease in the number and volume of gifts is confirmed by the analysis of the national “transparence-santé” database.[43] This decrease was used by doctors as an argument to trivialize the impact of sales rep visits on their practice. Although we can welcome the decrease in gifts, this trivialization may contribute to ongoing GP ambivalence towards sales visits. (added in the discussion – comparison with other studies)

Also please include a description of the current approach to oversight. See for example: https://www.has-sante.fr/jcms/c_1099657/fr/visite-medicale-accompagner-les-professionnels-et-les-etablissements; Habibi et al. Journal of Law, Medicine and Ethics. 2016; 44: 602-613; Reynolds et al. Health Policy 2018; 122(3): 250-255; Mintzes et al. JGIM 2013; 28(10): 1368–1375.

Done. (please see above - introduction)

In the focus groups described in Reynolds et al., we also found that a strong influence from the Mediator scandal in how the French GPs discussed sales rep visits. This is likely to have been influenced by timing of the focus groups but an open question is whether in the current interview study there was any spontaneous discussion of safety concerns and/or of Mediator.

Interviewed GPs spoke little about safety concerns and/or of Mediator. This has been added to the results:

“Interviewed GPs raised few safety concerns about meeting reps: “A few years ago, it had become the only source of information. I mean that those who didn’t read ‘La Revue Prescrire’, they’d prescribe; they followed the information brought by the visitors. It’s dangerous to do that! But that’s changed; it’s changed a lot.” None of them talked about the sales visit charter or drug-specific safety scandals.”

And to the discussion:

“In contrast to a study published in 2018,[44] physicians talked relatively little about regulations and did not talk about drug-specific safety scandals such as those regarding rofecoxib (Vioxx) and benfluorex (Mediator). This difference is likely due to the interview guide, which sought to explore the reasons for the discordance between attitude and behavior and did not allow these themes to emerge. Likewise, physicians did not talk about the sales visit charter, suggesting that it remains relatively unknown more than 10 years after its adoption. Instead, they described a decrease in the frequency of medical visitors and in the size of the gifts offered to them. This decrease in the number and volume of gifts is confirmed by the analysis of the national “transparence-santé” database.[43] This decrease was used by doctors as an argument to trivialize the impact of sales rep visits on their practice. Although we can welcome the decrease in gifts, this trivialization may contribute to ongoing GP ambivalence towards sales visits.”

As noted by Dr Lexchin, editing of the manuscript by an English-language editor would be helpful. There are a few repeated “false friends”. For example ‘laboratoires’ translates to pharmaceutical companies, not to labs. In English a laboratory or lab is a facility where scientific experiments of all types take place. A ‘lab scientist’ is someone using usually very expensive specialised equipment (in their lab) to carry out scientific experiments.

Thank you for these explanations. The manuscript has been thoroughly copy-edited by a native English speaker (Yvonne van der Does from the Office of International Scientific Visibility, Université Côte d'Azur)

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

Thank you, modifications have been brought thanks to these templates (font, figure captions etc.).

2. Please consider changing the title so as to meet our title format requirement (https://journals.plos.org/plosone/s/submission-guidelines). In particular, the title should be "Specific, descriptive, concise, and comprehensible to readers outside the field" and in this case it could be preferable to avoid undefined acronyms

Done.

3. We suggest you thoroughly copyedit your manuscript for language usage, spelling, and grammar. If you do not know anyone who can help you do this, you may wish to consider employing a professional scientific editing service. Upon resubmission, please provide the following: a) The name of the colleague or the details of the professional service that edited your manuscript b) A copy of your manuscript showing your changes by either highlighting them or using track changes (uploaded as a *supporting information* file) c) A clean copy of the edited manuscript (uploaded as the new *manuscript* file)

Done.

4. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For more information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

Datasets have been de-identified and are available in supporting information file S1.

5. Thank you for stating the following financial disclosure: "NO - The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript." At this time, please address the following queries:

Please clarify the sources of funding (financial or material support) for your study. List the grants or organizations that supported your study, including funding received from your institution.

State what role the funders took in the study. If the funders had no role in your study, please state: “The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

If any authors received a salary from any of your funders, please state which authors and which funders.

If you did not receive any funding for this study, please state: “The authors received no specific funding for this work.”

Thank you for raising this point. Indeed, the authors received no specific funding for this work. The financial disclosure has been modified directly in the editorial manager system.

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

Done. The authors received no specific funding for this work.

6. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please delete it from any other section.

Done.

7. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information

Done.

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

This paper does not contain any figures.

Reviewers' comments:

Reviewer #1: This is a qualitative study looking at why French GPs see sales representatives even though they generally have negative attitudes about the pharmaceutical industry. This type of inquiry is useful in formulating strategies about how to minimize the contact between these two groups and as such the authors should put forward policies towards that end based on their research.

We added in the discussion (line 560): “Studies showed that this topic was still not adequately addressed by medical authorities, even though ten years have passed since the benfluorex scandal which led to a profound crisis in the French health sector.[51–53] Some changes in the initial training could be introduced including our findings and previous suggestions: prohibiting professors from receiving gifts from sales reps, nudging them towards greater independence, providing a minimum curriculum for all medical students such as those already existing in France or elsewhere.[50,54–57] Continuing medical education could also be enhanced. GPs effectively felt the lack of free, non-biased and easy-to-access educational options that match their organizational constraints. French continuing medical education still suffers from a lack of independence and transparency in congresses and clinical practice guidelines despite the legal obligation for experts to disclose competing interests.[42,58] The development of convenient, non-biased, and individual continuing medical education is therefore a public health necessity.”

1. The English in many places is awkward and the entire manuscript should be copy edited by someone who has English as a first language.

Done. (see above)

2. It would help in commenting on the manuscript if the lines were numbered.

Done.

3. In describing how interactions with sales representatives influence prescribing the authors should cite some of the literature coming out of the use of the Open Payments database.

Done (line 95): “Financial relationships between the leaders of influential professional US medical associations and industry are extensive: 72% of them have financial ties to industry.[2]”.

4. Page 4: I think that it's highly likely that a portion of the medical profession is familiar with the terms cognitive dissonance and hidden curriculum and this sentence should be modified so as not to imply that it applies to the entire profession.

Thank you for raising that point. The sentence has been modified (line 88): “The GP/sales representative relationship is complex and involves psychological mechanisms that the medical profession tends to ignore such as cognitive dissonance and a hidden curriculum”

5. Page 4: The part of the sentence "complete the latter in a liberal field" is not clear.

We clarified this point as follows: « Sales representative visits act as a fast and easily accessible educational service that fills a need expressed by practitioners in France.»

6. Page 5: The authors should give a bit of background about general practice in France - how are doctors paid, do they generally practice alone or in groups, is there any funding for continuing medical education, do they also work in hospitals, etc.

We added the following details (lines 123-137): “A national fund for continuing medical education finances free courses for GPs and compensates for the loss of three days’ worth of medical fees while training. This non-biased continuing medical education is mandatory.[8] […] French primary care is mainly organized as a private, independent service, although financed by the public health insurance. Like most primary care providers in France, GPs mainly work in private practice and are paid on a fee-for-service basis. Group practice is now dominant among GPs and 81% of GPs younger than 50 declare that they work in a group.[15] Since the 2000s, teamwork in multidisciplinary primary care centers has been developed, mainly to maintain primary care services in low-income areas”

7. Page 5: USA should be spelled out in full the first time it is used.

Done

8. Page 5: The regulation of the activities of pharmaceutical representatives should be briefly described along with any penalties for violating the regulations.

Done: “The role of pharmaceutical sales representatives (sales reps) is regulated by the government through a Sales Visit Charter and a certification procedure but despite more stringent regulatory requirements than in North America, the information provided by sales reps remains poor.[5,6] The Sales Visit Charter Promotes good practices such as the presentation of approved product information including side effects and contraindications. Despite strict regulations (health authorities can impose fines of up to €10,000 or 10% of a product’s annual sales revenues) [7], the Sales Visit Charter is rarely respected.[5,6] Pharma sales reps are not allowed to follow continuing medical education courses”

9. Page 5: In what ways does the industry take part in the training of GPs?

We added the following details (line 111): “Initial and continuing medical education are supposed to be provided by impartial experts but these experts can be opinion leaders with financial ties to the industry.[9–12] Despite these measures, the pharmaceutical industry still plays an active role in research and in general practitioner (GP) training from the preclinical years to continuing medical education.[11]”

Moreover, “after the drug database Vidal, sales rep visits were the second source of information for practitioners.” (line 135).

To finish with, many congresses and reviews are funded by the industry.

10. Page 6: The authors should cite some of the literature showing that GPs believe in their own ability to resist being influenced by representatives but not necessarily in the ability of other GPs.

Done

11. Page 6: There should be a reference to the literature describing the phenomenological approach.

Done (Smith J. A, Flowers P, Larkin M. Interpretative phenomenological analysis: Theory, method and research. London: Sage; 2009. The methodological paradigm for this study was also specified.)

12. Page 7: The existing literature used to generate the interview guide should be cited.

Thank you for raising that point! It did not rely on a conceptual framework but only on the literature cited in the introduction. We changed to: “The interview guide was developed from existing literature[23] (identifying professional situations of uncertainty and reasons for meeting sales reps) and from two preliminary interviews.”.

13. Page 7: What GP details are the authors referring to? The city where the study took place is mentioned later but should be mentioned here. How did the authors determine if the GPs saw sales representatives? Did all GPs invited agree and if not how many refused?

GPs details has been replaced by “GPs’ phone numbers”.

The mention of the city has been moved here.

This part has been clarified as follows: “Participants were asked about these characteristics at the end of the interview” ; “Ten GPs refused to participate because of a lack of time.”.

14. Page 9: I'm not sure how to interpret the final sentence in the Methods section.

“The investigator’s motives and interests for the research subject have been questioned and analyzed beforehand within the research team.” This assertion relates to the COREQ criteria “What characteristics were reported about the interviewer/facilitator? e.g. Bias, assumptions, reasons and interests in the research topic”. This sentence has been reworded as follows: “The main investigator examined his own assumptions, and his reasons and interests for studying the research topic by brainstorming with the research team before the research started”

15. Page 9: How does peer group continuing education function in France?

Quality circles or peer groups are structured small groups of 6 to 12 health care professionals who meet regularly to reflect on and improve their practice. They also serve to develop professional networks. They are very popular in France, where participation can give rise to an indemnity when the group is accredited.[31]. Precisions have been added to the paper (line 211)

16. Page 10 (Table 1): What does "setting as a team" mean in the French context?

We meant « Group practice ». It has been clarified.

17. Page 10 (last paragraph): The first sentence is a repeat of what was said in the Introduction and Methods and should be deleted.

Done

18. Page 11: What does "counter-phobic effect" mean?

Clarified as follows: The participants attributed to rep visits a reassurance effect regarding their knowledge, and a “starter” effect as the first link of the information chain: meeting a sales rep was said to trigger more extensive research.

19. Page 12: What does “training session” mean?

We meant “course”. This part has been clarified.

20. Page 15: The part of this paragraph starting "Thus, these data..." is a conclusion and belongs in that section.

It has been moved.

21. Page 17: What “tendency” are the authors talking about?

Clarified as follows: “Several French GPs said that sales reps were fewer and brought gifts less often. Other observational studies arrived at the same conclusion.[24,43].”

22. Page 19: AMSA stopped publishing rankings in 2016.

Thank you. The sentence has been deleted.

Reviewer #2:

Dear authors,

Thank you first for this interesting and useful work. I used the Côté-Turgeon assessment grid (https://www.pedagogie-medicale.org/articles/pmed/abs/2002/02/pmed20023p81/pmed20023p81.html )

to evaluate your article and all the points listed got a yes, there are so only minor corrections to do according to me.

1) I would rephrase this extract like following:

Many studies show a correlation between receiving a gift from pharma reps or meeting them

and an amount of bigger, more expensive and sometimes less rational prescriptions [give here the corresponding references, this one should belong to them I think: https://bmjopen.bmj.com/content/7/9/e016408 ]. A recent study published in the BMJ confirmed this for French GPs through indicators such as prescription of antibiotics, benzodiazepines and vasodilators [4]

Done, thank you.

2) This situation is as much of a problem on the financial level (with costs that are indirectly born by the community via medication prices) as it is on the social, ethical and Public Health levels. [2]

You could add this more recent reference here: Public health and the interests of the pharmaceutical industry: how to guarantee the primacy of public health interests? European Parliamentary Assembly, 2015: http://semantic-pace.net/tools/pdf.aspx?doc=aHR0cDovL2Fzc2VtYmx5LmNvZS5pbnQvbncveG1sL1hSZWYvWDJILURXLWV4dHIuYXNwP2ZpbGVpZD0yMjAzMCZsYW5nPUVO&xsl=aHR0cDovL3NlbWFudGljcGFjZS5uZXQvWHNsdC9QZGYvWFJlZi1XRC1BVC1YTUwyUERGLnhzbA==&xsltparams=ZmlsZWlkPTIyMDMw

Done, thank you.

3) Therefore, while the role of industry in therapeutics and innovation is indisputable, must be encouraged and supported, the interest in the independence of prescribers is essential.

I disagree with this sentence, which for me corresponds more to the narrative of the pharmaceutical firms which wants to give themselves the best parts than facts. Prescrire showed that very few true innovative drugs have come to the markets in the last decades (Between 2002 and 2016, 52% of new drugs brought nothing new, 1% a real breakthrough, 6% an advantage, and 15% were not acceptable: Prescrire.Feb 2017; 37 (400): 133).

There are other arguments for this point that I presented in my PhD thesis (pages 24 o 31: https://formindep.fr/these-de-paul-scheffer/) and people like Marcia Angell, former editor in chief of the NEJM, argues at the end of her book the pharmaceutical firms should not participate to the research and the education in medicine and should rather concentrate their action only making the drugs available everywhere they are needed (The Truth about Drug Companies).

At last, there are numerous calls for giving more public financial support to the public medical research, which seems to be much better than supporting firms, with some examples given in this BMJ 2019 article https://www.bmj.com/content/367/bmj.l6576 )

You may simply put it this way: Therefore the interest in the independence of prescribers remains an essential goal, ten years after the publication of the Institute of Medicine report Conflicts of Interest in Medical Research, Practice, and Education (you could here use this recent reference: https://ebm.bmj.com/content/early/2020/11/11/bmjebm-2020-111503 )

Done, thank you.

4) However, their behavior remains rather positive towards medical industries, as they still predominantly receive pharmaceutical representatives (80% of practitioners in France). [7, 8]

Here you could use this more recent reference instead, which gives the same number: https://journals.openedition.org/regulation/11272 . I encourage the authors to read the whole paper to see if they are other elements that they would use for their article.

Done, thank you. Great paper!

5) No study exploring the determining factors of such a contradiction has been found in France.

I don’t agree totally with this sentence because there is at least one work addressing this issue, although not specifically, which is this article by the health anthropologist Anne Vega: https://www.cairn.info/revue-sciences-sociales-et-sante-2012-3-page-71.htmI think to these two extracts of this document:

Enfin, les représentants des firmes sont aux côtés des étudiants dès la faculté [20][20]L’ensemble de ces constats (développés dans Vega, 2011b) sont à…, ce qui les habitue ensuite à une présence jugée naturelle, peu « chronophage » et/ou aidante

Si les enquêtés font plutôt confiance à l’expertise des médecins spécialistes, c’est par manque de moyens de contrôle sur leurs prescriptions, mais aussi parce qu’ils accordent une valeur plus faible à leurs propres savoirs et à leurs expériences généralistes, le plus souvent jugés peu scientifiques [28][28]Souligné aussi par Bloy (2008).. Cette dévalorisation contribue également à limiter le partage de décisions avec les confrères généralistes, expliquant des difficultés observées à centraliser les dossiers de patients. Elle expliquerait surtout des recours privilégiés, voire exclusifs, aux avis et aux médicaments prescrits par les médecins spécialistes, ou vantés comme tels par les représentants des firmes pharmaceutiques. Les savoirs spécialisés ou experts restent en effet des gages d’assurance et de prestige, voire les seules références, chez de jeunes médecins. Ainsi, des enquêtés ont le sentiment de « ne rien savoir » au sortir des facultés et sont constamment à la recherche de « recettes ». Non seulement ils reproduisent des prescriptions spécialisées, mais ils ajoutent à leur propre panel de médicaments des produits spécialisés.

According to this, a formulation like the following one may be more accurate:

One qualitative study gave some elements of comprehension of the French GPs’ interactions with pharmaceutical sales representatives, like …, but no one tried to understand the contradiction why some general practitioners do receive the visits of pharmaceutical representatives while they convey a rather negative opinion towards pharmaceutical industries.

Done

6) Several GPs in our sample have mentioned that pharmaceutical representatives and their bringing gifts are now less numerous.

Jerôme Greffion arrived at the same finding, you could mention it: https://journals.openedition.org/regulation/11272

Done

7) You mention that among the interviewed GPs, one decided not to receive the reps anymore. Like Côté and Turgeon say (https://www.pedagogie-medicale.org/articles/pmed/abs/2002/02/pmed20023p81/pmed20023p81.html ), the deviant opinions are always very interesting to notice. Could he give some other reasons not mentioned by the others ?

Interestingly, this GP didn’t express a very “deviant opinion” with respect to the aim of our paper. The interview focused on his previous experience with meeting reps and the transcripts were analyzed in the same way as for the other participants.

8) About Limitations:

One limitation that could be added is the fact that the study, by its design, would not be able to collect elements of understanding 1) that would not be known by the interviewed doctors, for instance the fact that in France GP are quite isolated compared to the Dutch ones (see https://www.cairn.info/singuliers-generalistes--9782810900213-page-117.htm ), which would reinforce the feeling of young doctors not to know and to rely on the information given by the reps. Another element conducting to the same result could be the fact that French medical students integrate the idea that they don’t have the right not to know during their training (see https://formindep.fr/these-de-paul-scheffer/ pages 177 to 181 and https://journals.openedition.org/ethiquepublique/1818), or 2) that they don’t want to speak about, linked to the fact that this topic is rather taboo.

Added: “The study’s design did not allow the authors to collect elements of understanding unknown to the interviewed doctors, for instance the fact that in France GPs are quite isolated compared to Dutch ones.[45] This could have reinforced the feeling young doctors had of lacking knowledge and their need to rely on the information provided by the reps.”

9) This hypothesis has an external validity since some universities in the USA banned detailing visits

That is not exactly correct: A growing number of US hospitals and academic medical centers (AMCs) have guidelines that limit interactions between physicians and pharmaceutical sales representatives. 1 No AMC has completely banned detailing, or the promoting of drugs directly to physicians by pharmaceutical salespeople. However, some AMCs have limited detailing visits—for instance, by restricting visiting hours or locations. Another strategy employed by AMCs is to ban physicians from receiving gifts or sample products from sales representatives (https://www.healthaffairs.org/doi/10.1377/hlthaff.2013.0939 )

Done: “These observations lead us to consider the hypothesis that meetings with sales reps during initial training shape the GP-rep relationship which is then maintained over time by the three broad explanations described above. It has been demonstrated that the prohibition of gifts or samples has a positive influence on prescriptions well over several years after students leave the university.[46,47] These data bring external validity to our hypothesis.”

10) In 2017, Scheffer et Al. ranked French medical universities and teaching hospitals according to their management policy for interest conflicts. The study about teaching hospitals was published in 2019, not 2017.

Modified.

11) The authors state that French universities are behind a lot of countries, including the USA, despite French students willingness to learn [23-26]. Indeed, the American Medical Student Association (AMSA) has been publishing a yearly ranking of American universities since 2007, with much better results.

This is not true anymore today, if we would use the AMSA score card type, all French medical schools which voted the Deans’ Conference of medicine ethical charter of 2017 would receive an A. A formulation like this would be more accurate according to me: “Both studies showed that this topic was not adequately addressed by medical authorities yet, in spite of the ten years that have passed since the benfluorex scandal which led to a profound crisis in the French health sector. (suggested references: Mullard A (2011) Mediator scandal rocks French medical community. Lancet, 377: 890–892. pmid:21409784. Benkimoun P (2011) New law introduces tougher rules on drug regulation in France. BMJ 343: d8309. pmid:22194407. Fournier A, Zureik M. (2012) Estimate of deaths due to valvular insufficiency attributable to the use of benfluorex in France. Pharmaco Perlis, Roy H., et Clifford S. Perlis. « Physician Payments from Industry Are Associated with Greater Medicare Part D Prescribing Costs ». PLoS ONE 11, no 5 (16 mai 2016). https://doi.org/10.1371/journal.pone.0155474. epidemiol Drug Safety, 21: 343–351. Loi n° 2016–41 du 26 janvier 2016 de modernisation du système de santé français ). Some changes in the initial training could be fostered including our findings and precedent suggestions (https://www.pedagogie-medicale.org/articles/pmed/abs/2016/04/pmed170001/pmed170001.html )”

Thank you for this suggestion. This part has been modified as follows: “Studies showed that this topic was still not adequately addressed by medical authorities, even though ten years have passed since the benfluorex scandal which led to a profound crisis in the French health sector.[51–53] Some changes in the initial training could be introduced including our findings and previous suggestions: prohibiting professors from receiving gifts from sales reps, nudging them towards greater independence, providing a minimum curriculum for all medical students such as those already existing in France or elsewhere.[50,54–57] Continuing medical education could also be enhanced. GPs effectively felt the lack of free, non-biased and easy-to-access educational options that match their organizational constraints. French continuing medical education still suffers from a lack of independence and transparency in congresses and clinical practice guidelines despite the legal obligation for experts to disclose competing interests.[42,58] The development of convenient, non-biased, and individual continuing medical education is therefore a public health necessity”

Reviewer #3:

The authors conducted a qualitative, phenomenological study to understand better why GPs in France continue to see pharmaceutical representatives while maintaining a critical view of the pharmaceutical industry. This is an important topic, but is one that has been previously explored (Chimonas et al, 2009, Fischer et al, 2008, Prosser 2008).

Thank you for raising that point. Both of these papers tried to understand the reasons why GPs meet pharmaceutical representatives and their results are complementary with ours. The originality of our paper is to focus on understanding the discrepancy between GP opinions and behaviors. Both of these papers are discussed in the discussion of the revised manuscript.

One of the key markers of rigor in qualitative research is “congruency” – that is, that the research aims and question are grounded in the theoretical orientation of the researchers (ontology, epistemology, e.g. socially constructed knowledge), which is consistent with the methodology (e.g. interpretive phenomenology) and methods (e.g. interviews) selected. Within this project, there are frequently mismatches that threaten the congruency of this work and introduce threats to the quality of the research. Specifically, the researchers point to different disciplinary perspectives (“psychology, sociology and general practice”) as their theoretical grounding, but do not specify what these are or, how they worked together.

(i) Concerning congruency, we agree that it was not clear enough and we made the following modifications:

- INTRODUCTION SECTION

“This study explores GP experiences to better understand their ambivalence”

- METHODS SECTION

“An exploratory qualitative study was conducted based on a constructivist paradigm. An interpretative phenomenological approach was used to explore individual professional practices and to model the phenomenon through the in-depth analysis of singular experiences, of the meaning that participants gave to this experience and of underlying psychological mechanisms.[25].”

“The interview guide was developed from existing literature[23] (identifying professional situations of uncertainty and reasons for meeting sales reps) and from two preliminary interviews.”

“A convenience sampling method was used to select people with a range of experience in meeting sales reps. No specific inclusion or non-inclusion criteria were imposed since the research team considered that any GP could contribute new data to explain the phenomenon studied. The selection of practitioners was based on variation criteria for the following characteristics: […] These characteristics were expected to lead to a diverse sample of experiences and were based on the literature describing how the GP/rep relationship depends on social norms, age, patient list size and the type of continuing medical education.[4,23].”

“Transcripts were analyzed one interview at a time to explore individual perspectives. Texts were commented, then themes were coded, organized and finally formulated to identify common patterns shared by the different experiences.[25,27–29] Results were interpreted by a multi-field team composed of three GPs (AB, IP, TB), a sociologist (IF), and a social psychologist (IM).

“Data saturation was discussed and agreed upon by the research team when the sample was considered as gathering a wide range of experiences about relations to sales reps and no new theme emerged from the material analyzed. Theoretical validation was obtained by comparing the results with existing scientific data (see discussion)”

(ii) Concerning the diversity of disciplines collaborating in the project: this was not so much to provide a theoretical grounding but to anticipate the emerging elements of comprehension. Preparation with the workgroup was designed to better identify the emerging concepts and their theoretical groundings. We anticipated that concepts would relate to cognition but also possibly to social interactions: that’s why we gathered an interdisciplinary team. The manuscript modifications mentioned above add details about our grounding which related more to psychology and behavior, and justifies our phenomenological approach and the interview guide designed to explore personal experiences.

We added: “The heterogeneity of the team’s skills aimed at identifying themes more broadly and enlarging the scope of the analysis.”

The researchers in the methods section, state that they used “interpretive phenomenology” but it is unclear in which tradition (citations are missing) and the tenets of this approach are not explicitly stated.

Thank you again for this opportunity for clarification, modifications have been made (cf previous comment)

The methods chosen for sampling, interviewing and data analysis do not seem to be related to interpretive phenomenology (which emphasizes narratives, observations, and action over reflection). The relationship between the methods, the methodology and the theoretical perspectives needs to at minimum, be explicit.

Thank you again for this opportunity for clarification, modifications have been made (cf. preceding comment)

Finally, the researchers continue to mention “interpretive bias” in the methods and discussion and ways to mitigate this, however, the concept of “bias” is inconsistent with a qualitative, interpretive approach. Instead, the researchers should apply criteria for rigor that reflect research methods that emphasize the researcher’s role in data collection and analysis and that knowledge is socially constructed.

Yes indeed. This part has been rephrased to avoid the concept of bias. Our axiology paradigm considers researcher values as a perspective on the phenomenon and not a bias: “The impact of the personal values of the main investigator on the data collection process was controlled by a group identification of his preconceived beliefs and by training the investigator in semi-directive interview techniques. Their impact on the interpretive process was limited by a double analysis of every interview and by the diversity of approaches provided by the cross-disciplinary team”.

We also modified the Methods section to delete mention of a bias:

“Thematic extraction was triangulated to discuss and enrich interpretation from different perspectives: all interviews were analyzed first by the principal investigator, then by another researcher (GP, psychologist, or sociologist).”

It appears the sample is a convenience rather than purposive sample. Sampling could be strengthened if individuals were recruited based on theoretically informed (rather than merely demographic) criteria.

We specified that “A convenience sampling method was used to select people with a range of experience in meeting sales reps. No specific inclusion or non-inclusion criteria were imposed since the research team considered that any GP could contribute new data to explain the phenomenon studied. The selection of practitioners was based on variation criteria for the following characteristics: age, gender, rurality, years of practice, patient list size, single or collective practice, and subscription to a paying publication or membership to a peer group (see chart no. 1). […] These characteristics were expected to lead to a diverse sample of experiences and were based on the literature describing how the GP/rep relationship depends on social norms, age, patient list size and the type of continuing medical education.[4,23]”

These characteristics are indeed theoretically informed, based on the Anne Vega report : “These characteristics were expected to lead to a diverse sample of experiences and were based on the literature describing how the GP/rep relationship depends on social norms, age, patient list size and the type of continuing medical education”.

The researchers mention data saturation as a criterion for sampling; however, they do not demonstrate how they knew saturation was achieved and there does not seem to be sufficient presentation of the range of this phenomenon to suggest that they sampled the full range of this experience. This is not a critique of the sample size, but rather, that qualitative researchers must demonstrate to the reader that they sought contrasting perspectives and individuals with diverse experience until no new information arose.

We did specify the process: “Data saturation was discussed and agreed upon by the research team when the sample was considered as gathering a wide range of experiences about relations to sales reps and no new theme emerged from the material analyzed” The variety of profiles is described above in the Methods section (age, sex, type and frequency of contacts with pharma reps, habits about information seeking)

The researchers stated that this is an ‘exploratory’ analysis, but also seem to try and theorize this phenomenon. Thus, the aims of this work need clarification. If this is more of a theoretical analysis (around hidden curriculum, or cognitive dissonance, e.g. which I think would be of high value), then the theoretical perspectives informing this work and past work on this topic should be brought up front to really highlight what this work adds. At the moment, it is unclear which literature this work is in conversation with and the discussion really contains a lot of useful analysis, but fails to put it into context.

We hope that the modifications mentioned above managed to clarify this point. Our study was exploratory, without any concepts to test: the object was to understand a discrepancy between words and facts. During the research process, participants’ defensive attitudes made the interview guide evolve to a more progressive approach. The cognitive dissonance concept emerged from the inductive analysis.

At the moment, the analysis remains description, but could be greatly strengthened by incorporating the material in the discussion. The researchers should clarify whether they are applying particular theoretical perspectives, or are conducting a grounded, interpretive analysis (per the stated interpretive phenomenology), and then work to refine the results in either direction.

Citations have been added to illustrate the inductive process. Improvements in the method section are described above. The first paragraph of the discussion has been clarified as follows: In order to understand why some GPs meet sales reps while holding a rather negative opinion of the pharmaceutical industry, an inductive analysis led the authors to categorize the transcript into motivations, representations and values. Furthermore, the data suggested significant sociological and psychological mechanisms that can help explain the reasons for such ambivalence from GPs towards the pharmaceutical industry. The first part of the discussion describes these mechanisms: an experience-based rationale, self-efficacy, cognitive dissonance and a hidden curriculum.

This work is important and I encourage the researchers to continue this work. However, I think it may need to be reworked from the start to really clarify the aim, the theory/methods package, and to re-analyze the findings in this vein.

Thank you for your constructive comments. We hope that the revisions mentioned above achieved clarification.

Attachment

Submitted filename: 2021 05 30 GPs and pharma reps Answer to reviewers.docx

Decision Letter 1

Barbara Mintzes

25 Aug 2021

PONE-D-21-04814R1

General practitioners and sales reps: why are we so ambivalent?

Qualitative study in France comparing perspectives from sociology, psychology and general practice

PLOS ONE

Dear Dr. Barbaroux,

Thank you for submitting your manuscript to PLOS ONE. You have done an excellent job of responding to the comments on the previous review, especially in terms of clarifying the methods that were used. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

The manuscript currently reads well but there are still some problems with the English. Joel Lexchin has addressed many of the specific changes needed in his comments. However, the manuscript as a whole would also benefit from being read by a native English-language editor and overall stylistic editing. In some cases, 'false friends' are used - words in English that are similar to French words but have nuanced differences in meaning. An example is the use of 'representations' as a results section header and within the subsequent text. You have explained in the text that this term refers to the physicians' perceptions of the sales representative and of their interactions. However, calling this section 'Physicians' perceptions' would be clearer. When representations is used in the text, this could be better replaced by 'perceptions'.

Secondly, Lisa Parker's recommends a shift to how the content in the results and discussion sections, so that all quotes are included as part of the results, in keeping with standard practices for reporting of qualitative research. She also has some suggestions for organisation of content within sections that would make it easier for the reader to understand the key contrasting themes that surfaced in physicians' interviews.

Thirdly, table 1 would be more readable at a glance if these data were summarised. For example at the top you could just state n=10 and include one column for all GPs, rather than having a separate column per GP, urban setting could be 6 (60%);  Age: Mean (SD); range 30-59; extra fees charged 9 (90%); years in practice mean (SD); range 1-34; enrolled patients mean (SD); range 425-1500; workload (hours per week); mean (SD) etc.

The relevance of some rows (paid and free journal subscriptions) is unclear and for peer group you need an additional description of what the peer group is in the text. I am not sure if these were meant to be indicators of the type of practice the GP has, for example; "Reads commercially-produced free GP journals", or 'Subscribes to La Revue Prescrire' if this is what you were measuring. In the table the row header could be: 'Member of peer GP discussion group'. [or similar] The table should be understandable as a stand-alone item. 

In the comments below, one of Lisa Parker mentions not understanding what you meant by reps not following continuing medical education. I think 'following' may be the problem in this sentence - do you mean that they are not allowed to attend these classes (because of regulations or due to limits imposed by employers?) or that they cannot provide content within continuing education? If this is a comment on a requirement for independence of continuing medical education (e.g. non-sponsorship by industry) this would be an important point.

Please submit your revised manuscript by Oct 09 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Barbara Mintzes

Academic Editor

PLOS ONE

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: (No Response)

Reviewer #4: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #4: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: N/A

Reviewer #4: N/A

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #4: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

Reviewer #4: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The authors have dealt with my major concerns but there remain a number of minor issues, mostly language related, that need to be corrected.

1. Line 64: Rather than "incite" a better word would be "motivate".

2. The material starting "Cognitive dissonance..." on line 67 to the "hidden curriculum" on line 70 does not belong in the Results. It should be moved to the Discussion.

3. The sentence starting "The strength..." on line 70 should be moved to the end of the Discussion.

4. Line 94: Explain what "direct, indirect, and induced effects" means.

5. Line 97: Delete "prescription" and insert "prescribing".

6. Line 98: Delete "highest" and insert "largest".

7. Line 104; Promotes should start with a lower case p.

8. Line 107: I believe that "follow" should be "fund".

9. Line 129: Delete "prescription" and insert "prescribing".

10. Line 135: When the authors say "second source" do they mean second most frequently used source or second most trusted source?

11. Line 145: Insert "them with" between "provided" and "information".

12. Line 146: Own knowledge of what?

13. Lines 158-159: The authors should explain what they mean by a "constructivist paradigm" and "phenomenological approach".

14. Line 161: When the authors say "this experience" are they referring to interacting with sales reps?

15. Line 190: Use “conference” instead of “congress”.

16. Lines 209-210: What is a "paying publication"?

17. Line 210: Delete "to" and insert "in".

18. Line 213: What do "indemnity" and accreditation mean?

19. Line 220: What is a "thesis survey"?

20. Line 266: Does "verbatims" mean the verbal answers given during the interviews?

21. Line 299: What sales rep budget restrictions are the authors referring to?

22. Line 364: What do the authors mean by "reassessment"?

23. Line 371: Substitute "beliefs" for "cognition".

24. Line 407: Use "companies" instead of "industries".

25. Line 422: Substitute "observations" for "transcriptions".

26. Line 438: Sales visit charter has previously been capitalized.

27. Line 487: It should be “et al”.

28. Line 499: Use "conferences" instead of "congresses".

Reviewer #4: GPs and sales reps

Synopsis – this paper reports on an empirical qualitative study, involving interviews with GPs in France. The study focus is to explore the phenomenon whereby GPs regularly meet with sales reps, despite holding negative views about the pharmaceutical industry and sales rep marketing.

Overall comment - This is an important topic and empirical work is always a welcome addition to the literature. The current study contains useful data but could be greatly strengthened by further / clearer presentation of the analysis.

Major comments

I would have liked to see clearer presentation of the analytic work. At present it seems that the Results section is very descriptive, and the stronger analysis is buried in the Discussion section. I suggest re-ordering some of the text to incorporate the analytic work into Results. This would also adhere more closely to the standard results/discussion format of academic papers in the biomedical sector, where quotes etc are generally not placed in Discussion. For example, the authors could consider sectioning the Results into [a] negative views about sales reps [b] reasons for meeting with sales reps (need for quick information; valuing experience-based knowledge; habits acquired from medical school days via the hidden curriculum) [c] how GPs manage the cognitive dissonance (e.g. feeling that self is invulnerable to sales rep tactics etc.) Of course the authors do not have to follow this particular analytic structure, this is just one possible way that the analysis could be taken further to address the stated aim of trying to understand why this phenomenon is happening and what it’s like for the GPs on the ground. I see that the authors have already done a substantial revision in response to previous reviewer comments. Nevertheless, I think a further revision would greatly strengthen the paper.

Minor comments

Intro

p 5 line 103 – ‘the information provided by sales reps remains poor’ – what information and who is it provided to ?

P 5 line 107 ‘pharma sales reps are not allowed to follow continuing medical education courses.’ This comment is not clear to me, what do you mean?

P6 line 137 – ‘this situation is problematic on a financial level … and on a social, ethical and public health level.’ I probably agree with you, but I’d like some more detail here, can you spell out why it is problematic in each of these contexts?

Methods

P 8 line 181 was the preliminary interview data included in this study?

P 10 line 222 you talk about saturation here, but earlier you said that you were not aiming for saturation and it was not needed in a phenomenological study

P 10 line 230 I would like more information about why ethics approval was not required. Certainly in my country any studies involving human participants requires ethics approval, even when it is a low-risk study such as this one.

Results

P 11 line 253 it’s not useful to give 118 pages of transcriptions unless you provide the font, margins, line spacing etc; you could provide word count? Probably unnecessary; the number and average / median duration of interviews is sufficient I think

Strengths and limitations

P 19 line 446 small number of interviews is not always a limitation of a qualitative study, typically this is how qualitative research works. It would only be a limitation if you were unable to complete as many studies as you wanted to, e.g. if funding ran out or other reasons. In addition it is not always expected to get participants to review their transcripts, and I wouldn’t think this necessarily constituted a limitation unless there were particular reasons e.g. if the participants had strong accents and you were worried about transcribing their words correctly.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Joel Lexchin

Reviewer #4: Yes: Lisa Parker

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2022 Jan 24;17(1):e0261661. doi: 10.1371/journal.pone.0261661.r004

Author response to Decision Letter 1


8 Oct 2021

Response to reviewers:

Dear Barbara Mintzes, Academic Editor,

Dear Joel Lexchin and Lisa Parker , reviewers,

Thank you for giving us the opportunity to improve our manuscript once again. We have considered all your comments carefully. Please find below our point-by-point response.

Academic Editor reports:

The manuscript currently reads well but there are still some problems with the English. Joel Lexchin has addressed many of the specific changes needed in his comments. However, the manuscript as a whole would also benefit from being read by a native English-language editor and overall stylistic editing. In some cases, 'false friends' are used - words in English that are similar to French words but have nuanced differences in meaning. An example is the use of 'representations' as a results section header and within the subsequent text. You have explained in the text that this term refers to the physicians' perceptions of the sales representative and of their interactions. However, calling this section 'Physicians' perceptions' would be clearer. When representations is used in the text, this could be better replaced by 'perceptions'.

Thank you for this suggestion. A second native reviewer did a final polish of the English. All the changes suggested by Joel Lexchin have been taken into consideration and each occurrence of “representations” have been replaced with “physicians’ perceptions”.

Secondly, Lisa Parker's recommends a shift to how the content in the results and discussion sections, so that all quotes are included as part of the results, in keeping with standard practices for reporting of qualitative research. She also has some suggestions for organisation of content within sections that would make it easier for the reader to understand the key contrasting themes that surfaced in physicians' interviews.

Done (details below in the answer to the reviewer)

Thirdly, table 1 would be more readable at a glance if these data were summarised. For example at the top you could just state n=10 and include one column for all GPs, rather than having a separate column per GP, urban setting could be 6 (60%); Age: Mean (SD); range 30-59; extra fees charged 9 (90%); years in practice mean (SD); range 1-34; enrolled patients mean (SD); range 425-1500; workload (hours per week); mean (SD) etc.

Done. The table now looks like this :

Table 1. Characteristics of the ten GPs interviewed.

N = 10

(Mean ± SD [Range])

Age (years) 48,8 ± 9 [30-59]

Years in practice 15 ± 11 [1-34]

Enrolled patients 906 ± 439 [400-1500]

Hours p. week workload 55 ± 8 [43-65]

Number of sales reps p. week 3 ± 3 [0-10]

(n - percentage)

Extra fee charged 1 (10%)

Urban setting 6 (60%)

Group practice 5 (50%)

Subscribes to a paid medical journal 1 (10%)

Reads commercially-produced free GP journals 4 (40%)

Member of GP peer group 3 (30%)

The relevance of some rows (paid and free journal subscriptions) is unclear and for peer group you need an additional description of what the peer group is in the text. I am not sure if these were meant to be indicators of the type of practice the GP has, for example; "Reads commercially-produced free GP journals", or 'Subscribes to La Revue Prescrire' if this is what you were measuring. In the table the row header could be: 'Member of peer GP discussion group'. [or similar] The table should be understandable as a stand-alone item.

Done.

In the comments below, one of Lisa Parker mentions not understanding what you meant by reps not following continuing medical education. I think 'following' may be the problem in this sentence - do you mean that they are not allowed to attend these classes (because of regulations or due to limits imposed by employers?) or that they cannot provide content within continuing education? If this is a comment on a requirement for independence of continuing medical education (e.g. non-sponsorship by industry) this would be an important point.

Indeed, Pharma sales reps are not allowed to provide content for continuing education courses. This sentence was clarified in the text.

Reviewers' comments:

Reviewer #1: Joel Lexchin

The authors have dealt with my major concerns but there remain a number of minor issues, mostly language related, that need to be corrected.

1. Line 64: Rather than "incite" a better word would be "motivate".

Done

2. The material starting "Cognitive dissonance..." on line 67 to the "hidden curriculum" on line 70 does not belong in the Results. It should be moved to the Discussion.

Done

3. The sentence starting "The strength..." on line 70 should be moved to the end of the Discussion.

Done

4. Line 94: Explain what "direct, indirect, and induced effects" means.

Done : “In the United States of America (USA), the biopharmaceutical sector generates nearly $1.2 trillion in economic output annually when direct (biopharmaceutical industry revenue), indirect (vendor and supplier activity), and induced effects (additional private economic activity) are considered(1)”.

5. Line 97: Delete "prescription" and insert "prescribing".

Done

6. Line 98: Delete "highest" and insert "largest".

Done

7. Line 104; Promotes should start with a lower case p.

Done

8. Line 107: I believe that "follow" should be "fund".

Modified as follow : “Pharma sales reps are not allowed to provide content within continuing education courses”.

9. Line 129: Delete "prescription" and insert "prescribing".

Done

10. Line 135: When the authors say "second source" do they mean second most frequently used source or second most trusted source?

The report concluded that, after the drug database Vidal, sales rep visits were the second most used source of information (modified)

11. Line 145: Insert "them with" between "provided" and "information".

Done

12. Line 146: Own knowledge of what?

GPs also described a lack of confidence in their own pharmaceutical knowledge when leaving university (modified)

13. Lines 158-159: The authors should explain what they mean by a "constructivist paradigm" and "phenomenological approach".

Done : “An exploratory qualitative study was conducted based on a constructivist paradigm.[25] In this paradigm, qualitative research methods are considered as a means to allow the investigator to be the primary interpretive instrument and reality is considered as socially constructed and knowledge as a product constructed by people taking active part in a research process.[25] An interpretative phenomenological approach was used, that is, individual professional practices were explored and the phenomenon was modeled through the in-depth analysis of singular experiences, the meaning that participants gave to their experience of meeting sales reps, and the underlying psychological mechanisms.[26] The purpose of a phenomenological approach is mainly to shed light on the essence of a person’s experience in relation to a specific phenomenon, in this instance meeting sales reps despite holding a negative opinion of them.”

14. Line 161: When the authors say "this experience" are they referring to interacting with sales reps?

Yes (modified)

15. Line 190: Use “conference” instead of “congress”.

Done

16. Lines 209-210: What is a "paying publication"?

We meant a journal which charges a fee for subscription, this has been modified.

17. Line 210: Delete "to" and insert "in".

Done

18. Line 213: What do "indemnity" and accreditation mean?

Modified as follows : “can give rise to a government payment to members when the group is accredited (registered and recognized by the government)”

19. Line 220: What is a "thesis survey"?

We modified this sentence as follows : “The GPs were asked to answer a survey as part of an end of course medical thesis. The survey was presented to them as dealing with the information sources used by general practitioners, without mentioning promotional detailing visits.”

20. Line 266: Does "verbatims" mean the verbal answers given during the interviews?

In qualitative research, a transcript or verbatim is defined as a textual unit extracted from the transcription of the verbal answers given during the interviews, that can be smaller than a sentence. This has been clarified in the manuscript : “Transcripts, or excerpts of responses, can be grouped into the following categories: motivations, physicians’ perceptions, and values”.

21. Line 299: What sales rep budget restrictions are the authors referring to?

The sentence was unclear: participants referred to budget restrictions that have reduced the influence of the pharmaceutical industry. The sentence was reworded as follows: “The pharmaceutical industry’s persuasive force was described as belonging to a past era because current sales rep budget restrictions mean fewer reps and gifts: “There’s no more! There’s nothing left!””

22. Line 364: What do the authors mean by "reassessment"?

We meant self-questioning. Modified.

23. Line 371: Substitute "beliefs" for "cognition".

Done

24. Line 407: Use "companies" instead of "industries".

Done

25. Line 422: Substitute "observations" for "transcriptions".

Done

26. Line 438: Sales visit charter has previously been capitalized.

Thank you for noting this typo.

27. Line 487: It should be “et al”.

Thank you for noting this typo.

28. Line 499: Use "conferences" instead of "congresses".

Done.

Reviewer #4: Lisa Parker

Major comments

I would have liked to see clearer presentation of the analytic work. At present it seems that the Results section is very descriptive, and the stronger analysis is buried in the Discussion section. I suggest re-ordering some of the text to incorporate the analytic work into Results. This would also adhere more closely to the standard results/discussion format of academic papers in the biomedical sector, where quotes etc are generally not placed in Discussion.

Thank you for this comment, a former reviewer commented that “At the moment, the analysis remains description, but could

be greatly strengthened by incorporating the material in the discussion.”, which is the reason we added quotes in the discussion. Following your advice, quotes have been removed from the discussion, as in our former submission.

For example, the authors could consider sectioning the Results into [a] negative views about sales reps [b] reasons for meeting with sales reps (need for quick information; valuing experience-based knowledge; habits acquired from medical school days via the hidden curriculum) [c] how GPs manage the cognitive dissonance (e.g. feeling that self is invulnerable to sales rep tactics etc.) Of course the authors do not have to follow this particular analytic structure, this is just one possible way that the analysis could be taken further to address the stated aim of trying to understand why this phenomenon is happening and what it’s like for the GPs on the ground. I see that the authors have already done a substantial revision in response to previous reviewer comments. Nevertheless, I think a further revision would greatly strengthen the paper.

Thank you for this comment. We modified the structure of the paper to emphasize the concepts and psychosocial mechanisms involved in dealing with ambivalence: they were integrated in the results section, with dedicated subsections for clarity, and we reduced the repetition concerning pragmatism and evidence-based rationale. The hidden curriculum is still in the discussion section, as it relied less on data and can be considered more as explicative of the experience and perspective of participants.

There are no longer quotes in the discussion section.

Minor comments

Intro

p 5 line 103 – ‘the information provided by sales reps remains poor’ – what information and who is it provided to ?

Thank you for this comment, we modified this sentence as follows: “the information concerning drugs provided by sales reps to GPs remains poor”

P 5 line 107 ‘pharma sales reps are not allowed to follow continuing medical education courses.’ This comment is not clear to me, what do you mean?

Pharma sales reps are not allowed to provide content within continuing education courses. (modified)

P6 line 137 – ‘this situation is problematic on a financial level … and on a social, ethical and public health level.’ I probably agree with you, but I’d like some more detail here, can you spell out why it is problematic in each of these contexts?

We clarified as follows: “as much as on a social and ethical level (citizens’ demand for more transparency and more independent training for prescribers) and on a public health level because of potentially inadequate prescribing practices.(ref)”

Methods

P 8 line 181 was the preliminary interview data included in this study?

Yes. The data from the preliminary interviews was retained in this study, in accordance with the standards in qualitative research (27,29). (added)

P 10 line 222 you talk about saturation here, but earlier you said that you were not aiming for saturation and it was not needed in a phenomenological study

Indeed, the wording of the sentence could be considered confusing and has been removed. We left the following sentence in the text as a strength concerning the analysis process : “The research team discussed the data sample and considered that it gathered a wide range of experiences about relationships with sales reps and no new theme emerged from the material analyzed”.

P 10 line 230 I would like more information about why ethics approval was not required. Certainly in my country any studies involving human participants requires ethics approval, even when it is a low-risk study such as this one.

Data was collected before January 2016 in France. At this time, ethics approval was needed only for pharmaceutical research. In January 2016, the French “loi jardé” made ethics approval mandatory for some other kinds of research, such as non-pharmaceutical research involving patients. Currently, there is still no legal obligation to ask for ethics approval for this kind of research since the law does not consider qualitative research as research involving human participants. You can find out more at :

https://www.legifrance.gouv.fr/jorf/id/JORFTEXT000034634217

« Ne sont pas des recherches impliquant la personne humaine au sens du présent titre les recherches et qui visent à évaluer des modalités d'exercice des professionnels de santé ou des pratiques d'enseignement dans le domaine de la santé. » that we can translate as « Research involving the human person within the meaning of this title does not include research aimed at evaluating the methods of practice of health professionals or teaching practices in the health field. »

Results

P 11 line 253 it’s not useful to give 118 pages of transcriptions unless you provide the font, margins, line spacing etc; you could provide word count? Probably unnecessary; the number and average / median duration of interviews is sufficient I think

We agree with you, this information has been deleted.

Strengths and limitations

P 19 line 446 small number of interviews is not always a limitation of a qualitative study, typically this is how qualitative research works. It would only be a limitation if you were unable to complete as many studies as you wanted to, e.g. if funding ran out or other reasons. In addition it is not always expected to get participants to review their transcripts, and I wouldn’t think this necessarily constituted a limitation unless there were particular reasons e.g. if the participants had strong accents and you were worried about transcribing their words correctly.

Thank you for this comment, we do agree with you. This paragraph was reworded in order not to present it as a limitation.

The research team would like to thank the editor and the reviewers again for the quality of their reviews.

We look forward to hearing from you regarding our revised submission.

Sincerely,

Dr Adriaan BARBAROUX

On behalf of the research team.

Attachment

Submitted filename: 2021 10 08 GPs and sales reps Response to reviewers final.docx

Decision Letter 2

Barbara Mintzes

9 Dec 2021

General practitioners and sales reps: why are we so ambivalent?

Qualitative study in France comparing perspectives from sociology, psychology and general practice

PONE-D-21-04814R2

Dear Dr. Barbaroux,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Barbara Mintzes

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

I have an issue I would like to raise with you concerning data availability:

Supplementary file 1 was very interesting and includes some fantastic quotes beyond those in the article and the flavour of the discussion comes out strongly in the original French. Your openness in making it available publicly is also laudable. However, I am concerned that there are too many potentially identifying details within these transcripts, including interviewees mentioning names or places. It am concerned about breach of privacy.

My recommendations would be:

1) to ensure that making these transcripts available is consistent with the degree of protection of privacy offered to participants on the consent form.

2) If you would like to make the file available, I would also suggest that you only make this file available on request to other researchers and that before providing it, you read through all of the interviews and remove all potentially identifying information.

At my university, we are subject to ethics approval of interview studies and all transcripts must be kept confidential, sensitive or not. I also understand that there is strong legislated protection of personal privacy in the EU. Please ensure that any final data sharing decision is consistent with legal obligations. 

Additionally, usually if a data file such as this was made available, it would only be available as ‘raw data’ with no highlighting or other kinds of first-pass analysis.

I also wanted to discuss the reviewers' comments. Joel Lexchin has made two main suggestions:

  1. Shifting in the placement of large blocks text from results to discussion in several places;

  2. Copy-editing that is still needed.

My suggestion is that you look at his recommended changes in placement of text. If you feel that these shifts would strengthen the paper, please go ahead, but if not, it is fine for you to maintain the current organisation.

Some of the text in the results section would normally be included in the discussion in a medical journal article, but your explanatory text helps to frame the quotes in the results section and supports the approach to re-organisation that Lisa Parker suggested at a last stage, and that you have done an excellent job of implementing. I find the article to currently be very informative and readable and am happy to maintain the current structure, especially given that there is some extra flexibility in a report of a qualitative interview study.

For copy-editing, please do incorporate Joel lexchin’s recommendations:

1. It should be USA not US.

2. Line 174: “on” should be inserted after “commented”.

3. Line 213: “rurality” is not a word, use something like “rural location”.

4. Line 273: does "it" refer to the information received from sales reps or meeting sales reps?

5. Line 301: it should be "on" rather than "to".

I also had a few copy-editing suggestions:

The title should be:

"General practitioners and pharmaceutical sales representatives: why are we so ambivalent?"[remove the abbreviation ‘sales reps’]

Page 5, lines 104-105:

Despite strict regulations (health authorities can impose fines of up to €10,000 or 10% of a product’s 105 annual sales revenue) [7], the Sales Visit Charter is rarely respected.[5,6]

  • instead: “key provisions within the Sales Visit Charter, such as….  are rarely respected.” [e.g. please avoid overstating the case as administrative and certification policies are respected.],

P6, line 139: British GPs received visits. This should be, “British GPs reported that they received visits from sales reps for…”

P9, line 196: “…was chosen because it is in a situation of doubt…”

This should be: “…was chosen because of previous evidence that in a situation of doubt…”

P10, line 233:

“…and the quotations are not identified.” Perhaps instead: “…and no personal characteristics such as gender that might identify a speaker are attached to specific quotes.”

P11, Lines 236-7: “The authors declare that they did not receive …” should be, “The authors did not receive any funding for this study.”

P12, Table 1: Please left justify the text on the table left column and use rows that span the entire width of the table, including header rows. Please add a heading such as ‘demographics’ and ‘practice characteristics’ above the relevant sections.  I would suggest putting the table at the end of the manuscript, with a note such as [table 1 here] if you would like to specify its location in the txt. A table can be single spaced for ease of reading and the font size can be sans serif but should not be larger than the usual text font.

‘Extra fee charged’ should be “Patients charged extra fees”.  I would also suggest generally listing characteristics from the most frequent to least frequent (except that types of journals should be together). ‘p. week’ should be ‘per week’.

P12, line 265: “physician did not address the visit spontaneously, the interviewer raised the subject specifically” – please change ‘visit’ to ‘issue’.

P13, line 273, ”receiving sales rep visits despite their negative opinion about it.” – please change “negative opinion about it.” To “negative opinion about these interactions.”

Organizational problems that need to be corrected: 1. The material from lines 334-339 should be moved to the Discussion. 2. The material from lines 344-349 should be moved to the Discussion. 3. The material from lines 356-374 does not belong in the Results, except for the quotation on lines 364-366.

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: (No Response)

Reviewer #4: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #4: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: N/A

Reviewer #4: N/A

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #4: No

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #4: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: There are some organizational problems that need to be corrected:

1. The material from lines 334-339 should be moved to the Discussion.

2. The material from lines 344-349 should be moved to the Discussion.

3. The material from lines 356-374 does not belong in the Results, except for the quotation on lines 364-366.

There are also a few continuing copy editing issues:

1. It should be USA not US.

2. Line 174: “on” should be inserted after “commented”.

3. Line 213: “rurality” is not a word, use something like “rural location”.

4. Line 273: does "it" refer to the information received from sales reps or meeting sales reps?

5. Line 301: it should be "on" rather than "to".

Reviewer #4: (No Response)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Joel Lexchin

Reviewer #4: Yes: Lisa Parker

Acceptance letter

Barbara Mintzes

12 Jan 2022

PONE-D-21-04814R2

General practitioners and sales representatives: why are we so ambivalent? Qualitative study in France comparing perspectives from sociology, psychology and general practice

Dear Dr. Barbaroux:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Barbara Mintzes

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Checklist. COREQ checklist.

    (PDF)

    S1 Appendix. Interview guide.

    (DOC)

    Attachment

    Submitted filename: 2021 05 30 GPs and pharma reps Answer to reviewers.docx

    Attachment

    Submitted filename: 2021 10 08 GPs and sales reps Response to reviewers final.docx

    Data Availability Statement

    No - some restrictions apply There are ethical restrictions on sharing relevant data as data contain potentially identifying and sensitive information. For data access requests, researchers may contact the departement d'enseignement et de recherche en médecine générale, 28 Avenue De Vallombrose, 06107 Nice, France via laura.bruley@univ-cotedazur.fr. Researchers may also contact the corresponding author with data access requests.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES